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Age-related macular degeneration (AMD), the most common cause of vision loss 
for people age 50 and over, is a disease characterized by the buildup of oxidative stress in 
the back of the eye. Current remedies are limited to intravitreal injections that only target 
the more severe ‘wet’ form; the common ‘dry’ form has no readily available 
pharmaceutical solution. Curcumin, a natural antioxidant found in the Indian spice 
turmeric, has shown potential in combating inflammatory diseases like AMD; however, 
the molecule also demonstrates poor bioavailability. This research aimed to create 
curcumin-loaded nanoliposomes (NLs) to be delivered noninvasively to potentially treat 
and prevent the onset of AMD. The 220 nm NLs were composed of phosphatidylcholine 
and cholesterol through vacuum evaporation, rehydration, and extrusion. Our curcumin-
loaded NLs were assessed using an in vitro oxidative stress model of ARPE-19 cells. 
MTT cell viability assay results show that the liposomal curcumin complex has been able 





and cells that were damaged with peroxide (50% more viable, p < 0.05). As a 
preventative measure, the liposomal curcumin complex has been able to improve cell 
viability with respect to untreated cells (55% more viable, p < 0.05). Ex vivo modeling 
tested the permeability of the nanoliposomes to the posterior hemisphere of a porcine eye 
with a Franz diffusion cell apparatus. Qualitative fluorescence analysis shows that the 
nanoliposomes were able to permeate through different layers of the eye and reach the 
retina. In vitro studies with RPE cells show the treatment significantly reduces oxidative 
stress in cells while increasing cell viability, thus indicating that curcumin has potential to 
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Age-related Macular Degeneration 
Age-related macular degeneration (AMD) is one of the leading causes of vision 
loss in people over the age of 50. One of the primary theories for its pathophysiology 
pertains to harmful oxidative stresses in the retina (Lim, Mitchell, Seddon, Holz, & 
Wong, 2012). The onset of AMD occurs as a result of different environmental and 
physiological factors such as old age, obesity, tobacco use, and genes involved in 
significant signaling pathways (Lim et al., 2012). AMD damages the macula, the central 
region of the retina, which is mostly composed of millions of photoreceptor cells, causing 
the center of the field of vision to appear blurry or dark (National Eye Institute, 2013). 
This causes detrimental effects for the patients, as vision in the focal parts of their eyes is 
severely limited. 
There are generally two classifications to the disease, dry and wet AMD. The less 
severe, but more prevalent version of AMD is dry AMD (Lim et al., 2012). Dry AMD is 
characterized by yellow deposits called drusen that form under the macula. Over time, 
build-up of these drusen on the macula causes atrophy of retinal pigment epithelium 
(RPE) cells, ultimately leading to photoreceptor cell death and loss of central vision 
(Binder, Stanzel, Krebs, & Glittenberg, 2007). The other form of the disease is 
neovascular AMD, also referred to as wet AMD (Lim et al., 2012). Wet AMD is caused 
by abnormal blood vessel growth due to the malfunctioning of the signaling protein, 
vascular endothelial growth factor (VEGF). This results in the angiogenesis of fragile 
new blood vessels that are prone to leakage of fluids and lipids into the retina, thus 





percent of patients who are diagnosed with dry AMD are also diagnosed with the wet 
type (National Eye Institute, 2013). Thus, prevention and treatment of dry AMD is a 
significant focus of current research.  
Projections have shown that the number of people diagnosed with AMD will be 
around 196 million in 2020, and will increase to 288 million in 2040 (Wong, Su, Li, 
Cheung, Klein, Cheng, & Wong, 2014). The increase in diagnoses is especially relevant 
as researchers have predicted that more than two-thirds of affected patients, mostly  in 
Asia, Africa, and Latin America will not have access to expensive or invasive therapies 
(Wong et al., 2014). Therefore, it has become of vital importance to develop an effective  
treatment that can effectively prevent and treat AMD while still being affordable and 
easy to self-administer. 
 
Curcumin 
Curcumin, the biologically active component of turmeric, is used in traditional 
medicine for centuries. In Southeast Asia, turmeric has been used as an antiseptic for cuts 
and burns, and in other parts of Asia, it has been used to treat diseases associated with 
abdominal pain (Prasad & Aggarwal, 2011). Its antioxidant, anti-inflammatory, and 
antiproliferative properties make it a useful treatment for a variety of illnesses including 
retinal diseases such as AMD (Bhawana, Basniwal, Buttar, Jain, & Jain, 2011). Curcumin 
is thought to be successful in protecting RPE cells from oxidative stress, thus helping to 
prevent the onset of AMD (Woo, Shin, Lee, Joe, Zheng, Yim, Callaway, & Chung, 
2012). However, the integration of curcumin in the treatment of AMD according to 





(Pescosolido, Giannotti, Plateroti, Pascarella, & Nebbioso, 2014). As a result, curcumin is 
not yet an accepted method for the treatment and prevention of AMD. 
 
Justification for Research 
Though a variety of treatments exist to halt the progression of AMD, there is no 
cure to regain the loss in vision. Additionally, current FDA approved treatments are 
available for the wet form of AMD and there are no commonly accepted treatments 
available for dry AMD. The treatments for wet AMD involve monthly intravitreal 
injections that deliver anti-VEGF drugs to the retina. These intravitreal injections to the 
eye prove to be both invasive and time consuming for patients. One major focus in 
present AMD research is improving intravitreal treatments and to reduce the frequency of 
injections by combining the anti-VEGF drugs with photodynamic therapy and 
corticosteroids.  
A topical application through the form of eye drops would allow for ease of 
delivery of the drugs into the back of the eye. Additional research has also shown the 
benefits of utilizing nanoparticles as drug carriers for eye disease treatments. Studies 
have shown that nanoliposomes (NLs), nanoparticle vesicles formed from phospholipid 
bilayers, applied  via eye drops, may be effective drug carriers to the posterior segment of 
the eye (Hironaka et al., 2011). These studies introduce the possibility of using liposomal 
nanoparticles contained in eye drops to develop a topical treatment for AMD.  
We hypothesized that encapsulating curcumin within NLs would create a feasible 
and effective method of delivering curcumin to the retina. By manipulating a topical 





treatment option for AMD. There is research regarding preventative measures for AMD, 
however, none have proven to be effective thus far. As a result, AMD treatment and 
prevention is a vital and necessary area of research that is of great interest to people 
concerned for their vision. 
 
Research Questions and Hypotheses 
         The global aim of our research was to find a novel therapeutic compound to treat 
and prevent the progression of AMD by improving the bioavailability of curcumin 
through liposomal nanoparticle encapsulation to allow delivery to the RPE. We created 
curcumin-loaded NLs and tested them on ARPE-19 cell lines and excised eyes in order to 
answer the respective questions: (1) Can the curcumin-loaded NLs reduce oxidative 
stress levels in RPE cells without causing any cytotoxic effects? (2) Can the curcumin-
loaded NLs be incorporated in a topical delivery system that can effectively reach the 
target RPE cells? 
We hypothesize that the curcumin-loaded NLs would be successful in increasing 
the bioavailability of curcumin and thus reduce the oxidative stress levels in ARPE-19 
cells. Furthermore, we expect to see that the complex would be effective as a topical 
delivery system and would be able to travel through the layers of the eye without causing 














The basis of our treatment model stems from the use of curcumin, a component of 
turmeric, with antioxidant properties. Our approach to intraocular delivery of this 
hydrophobic compound was the use of a nanoparticle for noninvasive, topical 
application.. To select the most suitable material to encapsulate curcumin, we surveyed a 
selection of available nanoparticles for their chemical properties and physiological 
effects. We also surveyed standard protocols for synthesizing and characterizing drug-
loaded NLs, as well as methods for testing the treatment potential of a curcumin-loaded 
NL. 
 
Age-related Macular Degeneration 
AMD targets the macula, a small pigmented section of the retina. This area is 
composed of millions of photoreceptor cells, primarily the color-sensitive cone cells, and 
hence damage to this region causes the center of a person’s field of vision to appear 
blurry and dark (National Eye Institute, 2013). In particular, despite the small size of the 
affected region, the high concentration of photoreceptors means that central visual acuity 
is approximately ten times stronger than that of the periphery. This central vision loss 
thus accounts for a major loss of one’s sight. AMD is commonly divided into two forms: 
the less acute, but more prevalent “dry” AMD and the rapidly progressive neovascular, or 
“wet” AMD. Dry AMD is characterized by drusen, yellow deposits, forming underneath 
the macula. Many proteins and lipids have been found in drusen including apolipoprotein 
E (ApoE) and α, β-crystallin (Binder et al., 2007). Over time, the buildup of these 





early, intermediate, and late AMD. These stages are characterized by changes in the 
amount and size of drusen deposits, as well as the progression of RPE abnormalities. RPE 
abnormalities and vision loss are not seen until the intermediate stage. Data suggests that 
the progression between intermediate and late AMD typically occurs within 6.5 years. 
Symptoms during these stages include gradual vision deterioration, trouble adapting to 
changes in lighting, difficulty reading, and face recognition problems (National Academy 
of Sciences, 2015). 
Neovascular, “wet” AMD (Lim et al., 2012) can either develop on its own or as a 
progression of dry AMD. Wet AMD is caused by abnormal blood vessel growth under 
the retina, stimulated by VEGF, a signal protein for angiogenesis and vasculogenesis. 
These new vessels are fragile and prone to leaking and spontaneous hemorrhage. Scarring 
from these broken blood vessels causes irreversible damage to the macula. 
Approximately only ten percent of patients who are diagnosed with AMD suffer from the 
wet type; however, they experience more severe vision loss (National Eye Institute, 
2013). 
AMD is a multifactorial disease. As its name implies, the most significant risk 
factor for AMD is old age, as the likelihood of developing AMD increases substantially 
as a person grows older (National Eye Institute, 2013).  Recognized risk factors include 
cigarette smoking, Caucasian race, and positive family history. Other presumed risk 
factors include sunlight exposure, hyperlipidemia, hypertension, and vitamin deficiency.  
Various genes may play significant roles in the biological pathways related to the onset of 
AMD. For example, the VEGF-A gene is responsible for encoding the VEGF signaling 





Pathology. The pathogenesis of AMD is characterized by the degeneration of retinal 
photoreceptors, RPE, and Bruch’s membrane (Ding, Patel & Chan, 2008). Little is known 
about the precise mechanisms that lead to the disease due to the complex interactions of 
inflammation, apoptosis, cholesterol trafficking, angiogenesis, and oxidative stress, all of 
which play a role in AMD progression (Ding, Patel & Chan, 2008). However, oxidative 
stress is known to play a central role in AMD pathogenesis. Studies have shown that 
those with AMD have higher levels of carbohydrates and lipids that have been modified 
by oxidation (Howes et al., 2004). However, the mechanism through which this oxidation 
occurs is not well understood. It is known that oxidative stress occurs when the cell is 
exposed to reactive oxygen species, whose sources can be both exogenous and 
endogenous (Kohen & Nyska, 2002). These reactive oxygen species then generate toxic 
hydroxyl radicals and hydrogen peroxide, which damage the cell through reactions with 
proteins, DNA, and lipids and eventually induce cell death (Ding, Patel & Chan, 2008). 
The exact reaction between the toxic radicals/hydrogen peroxide and cell components is 
not well defined. 
AMD is asymptomatic in its early stages. It can be clinically diagnosed by finding 
drusen underneath the RPE, which appear as yellow spots in the macula. Although drusen 
accumulation is used to diagnose AMD, the mechanism through which it accumulates 
and its role in AMD pathogenesis and progression is unknown (Ding, Patel & Chan, 
2008). Patients with dry AMD lose vision gradually over the years, while those who 
develop wet AMD experience rapid vision loss. Central vision is blurry, and straight lines 
seem distorted, which is referred to as metamorphopsia (Lim et al., 2012). As 





which is referred to as scotoma (Lim et al., 2012). In the advanced stage of AMD, 
patients completely lose central vision. 
The RPE layer of eye tissue lies between the choroidal and neural tissues. The 
epithelial cells in this layer contain melanin, which aids in ensuring visual acuity by 
preventing light scattering. Additionally, the melanin granules absorb free radicals in 
order to protect the photoreceptors in the retina (Porte, 2012). However, melanin levels 
decrease with age, which leaves the retina vulnerable to the toxic effects of oxidative 
species. The toxicity leads to photoreceptor degradation (Curcio, Medeiros, and Millican, 
1996). Additionally, RPE cells are important in removing waste products from 
photoreceptor degradation. Once they are degraded, the outer rod and cone segments are 
absorbed by the RPE cell cytoplasm and are formed into lipofuscin granules by the 
lysosomes. These granules are then released into the bloodstream as metabolic wastes. 
However, levels of lipofuscin increase with age due to decrease melanin and overall 
antioxidant activity that lead to photoreceptor toxicity (Porte, 2012). The accumulation of 
lipofuscin granules, along with other waste products, leads to the build-up of drusen that 
characterizes dry AMD.  
Treatment. Although there is currently no definitive cure for AMD, recently, a variety of 
treatments have been developed for the wet form of AMD. Among the most effective 
treatments are anti-VEGF drugs, which combat abnormal angiogenesis. Ranibizumab, for 
example, is currently the most efficient in treating AMD. Clinical studies have shown 
that Ranibizumab prevented vision loss in 95% of patients and significantly improved 
vision in 40% (Rosenfeld et al., 2006). Bevacizumab is another successful anti-VEGF 





therefore a more popular choice of treatment (Gerson, 2009). Other effective anti-VEGF 
drugs include Aflibercept and Pegaptanib (Lim et al., 2012). However, despite the 
effectiveness of the anti-VEGF drugs, they have several drawbacks. Drugs like 
Ranibizumab and Bevacizumab require a strict regimen of monthly intravitreal injections, 
which are not only inconvenient, but also invasive with potential health risks (Lim et al., 
2012). Systemic side effects of these drugs include higher risks of strokes, myocardial 
infarctions, and other vascular complications (Lim et al., 2012). 
Several other experimental treatments with varying effectiveness are available. 
One such treatment is an RPE transplant (Binder et al., 2007). Pilot studies have shown 
that 57% of patients who underwent RPE transplantation saw their visual acuity improve, 
while 7% of patients had their acuity decrease. However, Binder et al. (2007) found 
several limitations. They could only use autologous RPE transplants, as allogeneic RPE 
transplants often induced adverse immune responses. The constraints of autologous 
transplants limited the graft size that was available for transplant and were not helpful in 
offsetting any genetic factors associated with the onset of AMD. Autologous transplants 
can also induce damage on the transplanted tissue during the surgery. Furthermore, RPE 
transplants have much higher safety risks than that of the anti-VEGF treatments, making 
them less than ideal for common AMD treatment, especially considering the prevalence 
of the disease. Another alternative is the implantation of synthetic telescope lenses, which 
is approved by the FDA to treat late stage AMD (Hudson et al. 2008). This telescope 
replaces the eye’s natural lens and essentially magnifies the field of vision while limiting 
peripheral vision. While effective, this surgery is invasive and comes with a set of risks, 





rehabilitation post-surgery, and other surgical complications. 
Prevention. Despite the recently developed treatments, prevention of AMD is of great 
importance, since AMD cannot be cured or reversed in its advanced stages. Most 
preventative measures include lifestyle changes to reduce the risk factors for AMD. 
Studies have confirmed that there is a positive correlation between smoking, excessive 
sunlight exposure, cardiovascular disease, and lack of proper diet and exercise to the 
onset of AMD (Snodderly, 1995). Eliminating preventable risk factors would help 
decrease the chances of developing AMD. Researchers have found that carotenoids and 
antioxidants play extremely vital roles in preventing AMD as they help protect the retina 
from oxidative stresses. Two carotenoids, lutein and zeaxanthin, have been found to be 
very important as macular pigments that specifically safeguard the macula from the 
destructive oxidative processes in the retina (Snodderly, 1995). The intake of these 
carotenoids as part of the diet has been found to be most beneficial, though the same does 
not hold true for blood carotenoids. Similarly, vitamins E and C have been found to 
demonstrate significant protective measures. High-dose antioxidants and minerals 
(mostly zinc) were found to delay progression of AMD from the early-intermediate 
stages to advanced stage (Age-Related Eye Disease Study Research Group, 2001). 
However, vitamin and antioxidant supplements are not completely effective in treating 
AMD or slowing its progression in its later stages. 
Current Research. AMD research efforts focus more on the treatment of AMD than its 
prevention, and in particular wet rather than dry AMD. One focus area has been 
improving anti-VEGF treatments by combining the anti-VEGF drugs with photodynamic 





combine the immediate and distinct improvements from photodynamic therapy with the 
longer lasting benefits of anti-VEGF drug therapy. Corticosteroids supplement the 
therapy with antiangiogenic and anti-inflammatory effects. But even this combination of 
therapy is often not effective. 
Current research is also looking towards the use of stem cell therapy to regenerate 
damaged retinal cells. Embryonic stem cells can be used to help replenish the loss of 
photoreceptor cells within the eye in patients with advanced AMD (Lim et al., 2012). 
Within AMD prevention research, one of the main focuses is improving screening and 
detection methods for AMD. Recent studies have reported progress in detecting AMD 
symptoms and markers from retinal photographs with a sensitivity and specificity rate of 
75% (Quellec, Russell, & Abramoff, 2011). Nevertheless, research on the prevention of 
AMD is still considerably limited. Further research could potentially help lessen the 
destructive effects of AMD by diagnosing the disease at an earlier stage. 
 
Topical Application 
Anatomy of the Eye. The anatomy of the eye is a significant barrier to treating AMD due 













Figure 2. Structure of the retina (© Alila Medical Media, standard license) 
Ocular-brain barriers act to selectively permit molecules into and out of the eye. In the 
front of the eye, the blood-aqueous barrier (BAB) is most relevant in cases involving the 
cornea and the lens. The blood-retinal barrier (BRB) governs the interaction between the 
retina and blood. The BRB is made up of two areas: one interacting with retinal vessels 
and one interacting with the choroid-RPE surface. These blood-ocular barriers are similar 
in that the inner BRB does not diffuse molecules larger than 20-30 kDa, while the outer 
layer tends to support diffusion of about the same nature, carrying in glucose and 






Figure 3. Location of ocular-brain barriers (Chen et al., 2008).  
Targeting the Posterior Eye. Permeability of a topical drug targeting the posterior region 
of the eye is a key factor in overcoming ocular barriers. Success depends on reaching the 
target cells while maintaining effective treatment capabilities. 
One study showed that a solution of the potential AMD treatment drug P2X 
antagonist pyridoxalphosphate-6-azophenyl-2',4'-disulphonicacid (PPADS), successfully 
reached the back of the eye.  The drug specifically protected the cells against cell lysis, 
indicating close interaction with the cells (Birke, Lipo, Birke, & Kumar-Singh, 2013). 
This treatment has relevance to our study by showing that topical application has the 
capacity to reach the target cells of interest in AMD. 
Encapsulation may be necessary for in vivo AMD therapy to increase the 
bioavailability of a drug. In this case, liposomes are an effective tool to reach the retinal 
cells of the eye. Of the surface modifiers tested, chitosan modification increased the 
efficacy of the drug the most (Sasaki et al., 2013).  





is crossing the various biological barriers of the eye. Choonara (2010) found that the 
ocular-blood barriers keep eye drops from being an effective treatment of posterior eye 
segment diseases. In an effort to develop a topical application of Avastin to treat AMD, 
Davis et al, (2014) used liposomes to encapsulate Annexin-5, a component of Avastin, to 
topically deliver to retinal cells within the rat eye. Liposomes successfully crossed the 
corneal epithelial barriers in order to reach the posterior of the eye (Davis et al., 2014).  
Modification of the liposome is also an important aspect of drug delivery. Sasaki et al. 
(2013) presented the potential to test the physicochemical properties of surface-modified 
liposomes in vitro, with success in application of the physicochemical properties when 
delivering drugs in vivo. The study specifically cites poly-L-lysine to modify the surfaces 
of the liposome (Sasaki et al., 2013). These case studies provide evidence that the use 
specifically of liposomal encapsulation makes reaching the back of the eye possible, and 
that surface modification may play a role. 
Improving Topical Applications. There are two main issues with topical drug delivery to 
the eye: penetration through the cornea and penetration through the blood-brain barrier.  
This results in low drug absorption. In a 2002 study, researchers found that the addition 
of cyclodextrins to the eye drop solution greatly enhanced the absorption of the drug 
(Loftsson & Stefánsson, 2002). It also increased the water solubility and stability of the 
drug. Another study ran into a similar problem of low drug absorption (in particular, 
delivering insulin via eye drops) (Xuan, McClellan, Moore, & Chiou, 2005). 
Modifications, such as an increase in pH to 8.0 and the addition of absorption enhancers 
like glycocholate and fusidic acid, allowed for greater insulin absorption. Another study 





surface-modified lipid emulsions could be used as a way to deliver the hydrophobic drugs 
to the ocular posterior segment of the eye (Ying, Tahara, & Takeuchi, 2013). 
Testing of Topical Application. Ex vivo studies have been used in order to evaluate the 
efficiency of eye drops in various animal models. Many of these studies have focused on 
targeting the cornea, in the anterior of the eye, though there are some that have 
demonstrated the potential for retinal drug delivery. For instance, bovine eyes were 
excised and used in order to determine how effectively luteinizing hormone-releasing 
hormone (LHRH) permeates the cornea and the other parts of the eye. The study found 
that the hormone localized to parts of the ocular endothelium, but not the vitreous. 
Evaluation of topical treatments to the back of the eye has been challenging, as the RPE 
is highly selective. However, a study by Kansara and Mitra (2006) demonstrated that 
mannitol could diffuse to the retina via the sclera and that permeability did not differ 
significantly between the sclera → retina pathway and the retina → sclera pathway. 
 
Curcumin 
Physiochemical Properties. Within the last decade, many scientists and researchers have 
discovered the therapeutic benefits of curcumin, an extract from the Indian spice turmeric 
with chemical formula C21H20O6 (see Appendix B for the complete structure) and 
molecular weight 368.38 g/mol. Although curcumin has been commonly used in 
traditional and holistic medicine therapies, its use in clinical medicine has been limited 
due to its low solubility (< 0.1 mM in water) and its resulting poor bioavailability 
(Yadav, Suresh, Devi, & Yadav, 2009). However, multiple studies have found that 





that curcumin-loaded lipid-based nanocarriers reduced MPO and TNF-α enzyme activity 
in vivo, both indicators of inflammatory responses brought on by colitis (Beloqui et al., 
2016. Kant et al. found that the antioxidant and anti-inflammatory properties of curcumin 
accelerated the cutaneous wound healing of diabetic rats. Curcumin was found to 
decrease the expressions of inflammatory enzymes and increased wound contraction 
(Kant et al., 2014). These long studied anti-inflammatory and antioxidant properties have 
more recently been studied across many diseases characterized by inflammation and 
oxidation. The goal of many of these studies is to increase the bioavailability and 
retention of curcumin in the body to improve efficacy of these treatments.  
Curcumin is a free radical scavenger and can regulate cellular signal transduction 
pathways, which makes it potentially useful in treating cancer, neurodegenerative 
disorders, and diabetes (Calabrese et. al., 2008). Curcumin’s capability to regulate 
mitochondrial processes and ATP production gives it a rare potential to treat and possibly 
prevent oxidative stress (Molina-Jijón et al., 2011). In addition, curcumin can down-
regulate transcription factor NF-kB and NF-kB-regulated gene products, which have been 
linked to the onset of several chronic inflammatory diseases (Mandal et al., 2009). These 
properties of curcumin make it a candidate for treating the oxidative damage and 
inflammation related to AMD. 
Retinoprotective Properties. Curcumin’s ability to act as a retinoprotective agent has 
been shown in models of diseases induced by oxidative stress to the retina, including 
AMD (Fiorentino, Prioletta, Zuo, & Folli, 2013; Salem, Abdel-Rahman, Ewias, & 
Tsegay, 2012; Woo et al., 2012). Curcumin has been able to reduce the oxidative stress in 





reactive oxygen species (ROS) production (Fiorentino et al., 2013; Woo et al., 2012). 
ROS pathways have also been shown as a possible mechanism for the development of 
AMD (Woo et al., 2012). Aside from RPE cells, curcumin has been shown to protect 
other cells in the eye.. For instance, curcumin has been shown to protect the cornea 
against nicotine-induced toxicity, which is an important risk factor for eye-related disease 
(Karam, Issa, Mohamed, & Hassanin, 2014). However, curcumin’s ability to reverse pre-
existing AMD damage has not been established. 
Improvement of Visual Acuity. Mirza et al. (2013) found that curcumin and 
docosahexaenoic acid (DHA) worked well together and that the mice given both as a 
dietary supplement had significantly higher visual acuity compared to that of the control 
mice, while weakening the progression of retinal degradation. Mazzolani (2012) studied 
the lipid-based encapsulation of curcumin and found that it was effective in improving 
visual acuity for patients suffering from central serous chorioretinopathy. 
Cytotoxicity Limitations. Despite the benefits of curcumin as a potential drug for 
treatment of AMD, there are some cytotoxicity concerns to consider. Several studies have 
demonstrated that greater than 20 µM doses of curcumin in the eye do not show 
therapeutic effects (Hollborn et al., 2013), and prolonged exposure affected caspase-3 
activation, which can lead to necrosis and delayed apoptosis. These mechanisms are still 
being investigated. The bioavailability of curcumin has been shown to peak around 15 
µM, where expression of HO-1 was highest (Hollborn et al., 2013). Although high 
concentrations of curcumin cause cell damage and death, a lower, controlled dosage still 
has potential to prevent the progression of AMD and other diseases involving oxidative 





change given encapsulation of the drug. MTT assays may be used to evaluate this 
cytotoxicity when incorporated into a complex. 
For molecules whose biodegradable properties are not as well known, Anitha et 
al. (2011) used an MTT assay to measure the cytotoxicity of carboxymethyl chitosan (O-
CMC)-curcumin complexes. They measured cell uptake through cell culture studies and 
tracked curcumin molecules under a fluorescence microscope. This method also 
confirmed whether or not curcumin was actually released by the chitosan carrier. The 
study found that this chitosan derivative alone is not cytotoxic, while curcumin and the 
O-CMC-curcumin complex are cytotoxic only to cancer cells. The cell uptake results also 
showed a considerable increase in uptake of the curcumin when encapsulated by O-CMC, 
compared to that of free curcumin. 
Clinical Targets. Several clinical trials have attempted to improve the biosolubility of 
curcumin by encapsulating it in a carrier. For instance, Marczylo et al. and Allegri et al. 
studied Norflo tablets in clinical trials to treat uveitis, which, like AMD, is characterized 
by inflammation in the eye . They used a phosphatidylcholine-based vesicle, to orally 
deliver curcumin. This was shown to significantly improve curcumin’s bioavailability 
and tolerability (Marczylo et al., 2007; Allegri, Mastromarino, & Neri, 2010). Another 
study conducted by Shaikh, Ankola, Beniwal, Singh, & Kumar (2009) showed that 
PLGA (poly(lactic-co-glycolic acid)) nanoparticles improved oral bioavailability 9-fold 
and allowed a sustained release of curcumin for a period of 48 hours. One way in which 
encapsulation improves bioavailability is by increasing curcumin’s half-life. A study 
done by Anand, Kunnumakkara, Newman, and Aggarwal in 2007 found the half-life of 





curcumin was encapsulated in liposomes (Anand, Kunnumakkara, Newman, and 
Aggarwal, 2007). Their results demonstrate the successes in using nanoparticle 
encapsulation to overcome the limitations that come with using curcumin. 
 
Nanoparticles 
The use of nanoparticle technology has greatly increased in medicine, and 
especially in the field of retinal drug delivery. Nanoparticles range in size from 1 to 100 
nanometers in diameter. They act as whole units in terms of transport and physical 
characterization and offer favorable properties of both bulk materials and molecular 
structures. The increased surface-area-to-volume ratio in nanoparticles also provides 
various opportunities for modification (Taylor et al., 2013). Nanoparticle drug delivery 
systems have particular potential in treating dry AMD in the posterior segment of the eye 
due to their capabilities in defying ocular barriers, targeting retina, and enhancing 
permeation, all while providing a controlled release (Kaur & Kakkar, 2014). However, 
there is also a delicate balance between a nanoparticle’s capabilities and limitations that 
must be considered. In selecting the best-suited carrier for curcumin-encapsulating 
nanoparticles, we considered factors such as toxicity, size, biodegradability, stability, and 
feasibility of synthesis. 
Magnetic Nanoparticles. Magnetic nanoparticles are becoming increasingly popular in 
ocular applications. Due to their surface properties and controlled manipulation for 
specificity, they have been utilized in various eye disease therapies. Their ability to be 
tracked by MRI also allows for a more controlled monitor of their movement and 





nanoparticles that were intravenously injected localized in the RPE layer within 24 hours 
of delivery, suggesting their capabilities to challenge ocular barriers. The nanoparticles 
were retained within the ocular compartments for a longer period of time without 
disturbance from external influences. However, these properties have not yet been 
explored in mammalian organisms (Giannaccini et al., 2014). Furthermore, the lack of 
information that is attributed to these types of nanoparticles and their effects in 
encapsulation make it difficult to quantify their significance in drug delivery treatments. 
Hydrogel Nanoparticles. Hydrogel nanoparticles have long been valued as a 
biocompatible drug delivery system due to their unique combination of hydrophilicity, 
high water content, and small size. These properties make them ideal for cellular drug 
delivery. Hydrogels are known for resembling living tissue cells more than any other type 
of synthetic biomaterial. However, the complexity of their release mechanisms also 
results in a complex balance in the development of these hydrogel nanoparticles, making 
them difficult to work with and to accurately produce (Hamidi, Azadi, & Rafiei, 2008). 
Chitosan is a hydrogel that is a natural biopolymer produced by the fermentation 
of microorganisms (Rampino, Borgogna, Blasi, Bellich, & Cesàro, 2013). Chitosan, 
because of its natural composition, exhibits low cytotoxicity and soft tissue compatibility 
(Liu et al., 2013). Additionally, due to its precision time-release delivery, it can be used at 
both intra and extraocular levels (Agnihotri, Mallikarjuna, & Aminabhavi, 2004). It has 
been tested extensively as a nanoparticle that can encapsulate and deliver drugs for the 
treatment of many medical issues, from inflammation to cancer. Chitosan-curcumin 






Polymeric Nanoparticles. Polymeric nanoparticles (PNPs) are made from various 
polymers and are also biodegradable, nontoxic, and nonimmunogenic. PNPs have been 
shown to non-toxically stay in cells for up to four months whilst continuously delivering 
drugs; this capability proves extremely beneficial in the long-term treatment of diseases. 
PNPs have been used extensively with curcumin to treat cancer. For instance, the study 
conducted by Bisht showed that encapsulating curcumin in PNPs successfully made the 
hydrophobic curcumin soluble in aqueous solution, allowing the body to uptake the 
curcumin and benefit from its antioxidant effects (2007). PNPs offer many advantages in 
controlled ocular drug release, as they can track the location of fluorescently labeled 
particles (Kaur & Kakkar, 2014). However, research also suggests that PNPs exhibit poor 
batch-to-batch reproducibility, which could prevent consistent experimentation and 
robust evaluation of the nanoparticle’s therapeutic ability (Jawahar & Meyyanathan, 
2012). While PNPs show much promise in the future, there is not enough current research 
to conclude that they have applications on the intraocular level. 
Liposomes. Liposomes are amphiphilic compounds composed of a lipid bilayer and an 
aqueous compartment, allowing for full encapsulation of polar and nonpolar drugs (Kaur 
& Kakkar, 2014). Although liposomes may be difficult to load with drugs and have a 
relatively short shelf life, recent studies have shown that these limitations can be 
addressed through further manipulation of different variables (Meerovich et al., 2008). 
For example, the addition of polyethylene glycol (PEG) and surface proteins on these 
nanoparticles have allowed for improvements on long-circulating liposomes (Nguyen et 
al., 2008). Furthermore, liposomal targeting can easily be manipulated through the 





nanoparticles can also be utilized to target AMD and other retinal disorders. In a study 
conducted by Davis et al. (2014), Annexin A5-treated liposomes were utilized to deliver 
Avastin to the posterior region of the eye through a topical application. These 
nanoparticles were able to successfully cross the ocular barriers and deliver Avastin to 
the designated location, thus hinting at a sufficient transfer of liposomes into ocular 
compartments from an alternative route of delivery. 
Lipid-based nanoparticles, or NLs, appear to be the appropriate carrier for a 
curcumin-laden nanoparticle to the posterior segment of the eye. This can be attributed to 
a combination of factors such as the low cost of production, amphiphilic nature, targeting 
capabilities, and previous success in similar endeavors. Potential setbacks, such as NLs’ 
relatively short shelf life, can be improved by additional surface attachments. These 
aspects of lipid-based nanoparticles both for and against their use in topical applications 
have been carefully weighed to maximize the potential for success in delivering curcumin 
antioxidants to the RPE. 
Lipid-based carriers are appropriate for cellular drug delivery because of the 
target’s high lipid content. Nanostructured lipid carriers, when used to deliver the drug 
Zidovudine, exhibited high drug permeation in the body, and low toxicity  (Gomes, 
Neves, & Sarmento, 2014). In addition, albumin, a matrix-forming macromolecule, was 
found to have high drug localization in the brain, high biodegradability and low toxicity. 
This highlights the lipid-based carriers’ distinctive attributes, as the high biodegradability 








The biophysical interactions of drugs such as curcumin with lipid membranes can 
be modeled by using a Langmuir model system. In this system, a well-defined and stable 
lipid monolayer can be formed on the surface of a liquid subphase using a Langmuir film 
balance. Using this monolayer, the interaction of drugs and drug delivery systems with 
lipids can be characterized through two different methods (Peetla, Stine, & Labhasetwar, 
2009). One such technique involves compressing the lipid monolayer to a constant 
surface pressure. The drug or drug delivery system of interest is added to the subphase 
under constant film area and the subsequent changes in the surface pressure are recorded. 
The second method calls for a mixture of lipids and drugs to be spread on top of a 
subphase to form a monolayer. This monolayer is gradually compressed to create a 
surface pressure-film area isotherm, which is then compared with the isotherm of the pure 
lipid. 
The Langmuir model can be used to determine the rate of drug penetration, 
maximum amount of drug penetrated and the saturation pressure of the membrane (Feng 
& Chien, 2003). Previous studies have extensively detailed the effects of drug penetration 
on the changes in surface pressure. One such study looked at paclitaxel, a 
chemotherapeutic drug, penetration into dipalmitoylphosphatidylcholine (DPPC) lipid 
membranes in order to model drug delivery to cervical cancer cells (Preetha, Huilgol, & 
Banerjee, 2006). Researchers specifically monitored the surface pressure changes. It was 
found that an increase in surface pressure with respect to time was due to the penetration 
of the drug while the eventual constant values with respect to time indicated the 





understood to be the result of the partial desorption of drug molecules from the 
monolayer while a negative surface pressure indicated the collapse of some of the 
monolayer into the subphase (Gicquaud, Chauvet, & Tancrède, 2003). Researchers have 
also investigated the effects of cholesterol on drug penetration. It was found that the 
addition of cholesterol to the DPPC lipid monolayer increased the membrane rigidity and 
significantly limited paclitaxel penetration (Zhao & Feng, 2006) 
Additionally, the Langmuir trough has been used to investigate monolayer and, by 
extension, vesicle stability. As previously mentioned, a decrease in surface pressure after 
the addition of a drug indicates the desorption of lipid molecules into the subphase. This 
in turn suggests the destabilization effects of the drug at hand, as it disrupted the 
previously ordered structure to cause the some collapse into the subphase. One study 
specifically looked at the interactions of curcumin with monolayer and bilayer lipid 
membranes (Karewicz et al., 2011). Egg yolk phosphatidylcholine (EYPC) was used as 
the main component of the lipid membranes though cholesterol and dihexadecyl 
phosphate (DHP) were added to understand the effects of curcumin on the stability of 
mixed systems. As curcumin inserts itself preferentially into the liposomal bilayer, the 
vesicle characteristics are a direct result of the curcumin interactions with the lipid 
components of the vesicle. Karewicz et al. modeled these effects through a Langmuir 
monolayer model. They found that curcumin initially increases the particle size as its 
insertion into the membrane introduces stiffness to the layer. However, with increasing 
amounts of curcumin added, curcumin destabilizes the ordered lipid structure and 
decreases the particle size. Vesicle stability was also influenced by the addition of extra 





negatively charged liposomes that would have additional stability due to their 
polycationic coating. Isotherms of the EYPC/DHP and EYPC/DHP/Curcumin were 
similar, indicating that curcumin had similar interactions with the EYPC/DHP monolayer 
as it did with the pure EYPC monolayer. As such, the introduction of DHP to the 
monolayer was not effective in increasing the curcumin penetration. Cholesterol was 
included to the EYPC/DHP system to stabilize the liposomes as well as to limit drug 
leakage. Cholesterol was seen to insert itself into the bilayer in a method analogous to 
curcumin molecules. Cholesterol has a strong ordering influence on the monolayer 
structure, which counteracts the destabilization effect of curcumin. Cholesterol was found 
to be an advantageous addition to monolayer as it stabilized the overall liposome system 
proportionally to the curcumin loading content. EYPC/DHP, in contrast, destabilized 
quickly at drug loading. These results indicate that a mixed system of lipids and 
cholesterol is the most advantageous composition for effective drug loading and delivery. 
 
Methodology Justification 
We evaluated previously described methods for the synthesis of the curcumin-
loaded NLs, in vitro testing, and ex vivo testing of the delivery system. This section aims 
to discuss procedures that were utilized for the project vision. 
Curcumin-loaded Nanoliposome Synthesis Procedures. When synthesizing our 
curcumin-loaded NLs, we aimed to use a molecule susceptible to biodegradation so that it 
may be easily flushed out of the body. Some options included PLGA, which was tested 
by Grama et al. (2013) for its ability to improve the bioavailability of curcumin. In 





complex. PLGA was chosen for its well-known biodegradable and biocompatible 
properties. The loading of curcumin was done through stirring and suspension methods, 
followed by purification using an emulsion-diffusion-evaporation technique. The 
resulting pellet was then resuspended and freeze dried for storing in order to increase the 
drug’s shelf life; characterization was carried out via dynamic light scattering at each 
major step and the study found no nanostructural discrepancies between the freshly-
prepared stock and the freeze dried stock. Although the in vivo methods are outside the 
scope of this project, it should be noted that the results demonstrated a 9-fold increase in 
the peroral bioavailability of curcumin. These techniques can be combined with other 
lipids, to create a similar increase in bioavailability. 
Studying liposomes as well, Puri et al. (2011) integrated fluorescent lipid probes 
into the synthesis procedure mixing in 0.5% mol lissamine rhodamine B before freeze-
drying the lipids. They used fluorescence imaging to detect the conformation of different 
lipids in the bilayer. 
Measuring Oxidative Stress. The retina is susceptible to oxidative stress on a daily basis 
due to its high oxygen consumption, great proportion of polyunsaturated fatty acids, and 
exposure to visible light (Totan et al., 2009). As mentioned previously, oxidative damage 
has a large role in the pathogenesis of AMD; therefore it is important to quantify 
oxidative stress when doing research on AMD. 
Levels of reactive oxygen species (ROS) are important biomarkers to test. ROS 
are molecules that are produced as a result of aerobic metabolism and respiration and 
include hydrogen peroxide (H2O2), superoxide anion (O2-), and hydroxyl radicals (OH-). 





damage to various biomolecules within the cells (Schieber & Chandel, 2014). By 
measuring ROS levels within the cells, it allows for another direct quantification of the 
oxidative stress that has been induced within. In addition to testing for ROS levels as a 
whole, it is also beneficial to look at biomarkers that target a specific component of ROS. 
Superoxide dismutases (SODs) are antioxidant enzymes that can convert a component of 
ROS, superoxide anion (O2-), to hydrogen peroxide (H2O2) and molecular oxygen. These 
are then further converted into water by other enzymes. This function allows SODs to 
serve as a principal defense system to protect biomolecules from oxidative stress and 
damage as these toxic molecules are converted to an innocuous product (Weydert & 
Cullen, 2010). The presence of significant amounts of SODs within a cellular 
environment indicate that concentrations of superoxide anion are kept low, and thus by 
measuring SOD levels, it allows for a quantification of the antioxidant activity in 
response to oxidative stress within the cells (Weydert & Cullen, 2010). The various 
biomarkers and steps offered for measuring oxidative stress should be taken before and 
after applying an experimental treatment in order to efficiently evaluate the effectiveness 
of the treatment. 
Demonstrating Complex Permeation. A method to test complex permeation ex vivo is 
simulated posterior eye diffusion via a Franz diffusion cell. The tissues of interest are 
placed in the apparatus; with the drug solution placed in the donor chamber and simulated 
tear and vitreous fluids in the receptor chamber (Kaskoos, 2014). This process allows 
more control than submersion methods, as one can decide which tissues (i.e. which layers 







SUMMARY OF AIMS 
Our research process was divided into three aims in order to better answer our 
overarching research questions. These aims include: 
I. Creation of curcumin-loaded NLs in order to improve the bioavailability of 
curcumin. 
II. Determination of the curcumin-loaded NLs’ ability to allow significant release of 
curcumin into RPE cells and to reduce oxidative stress.  
III. Demonstration of a topical delivery application for the curcumin-loaded NLs in 
order to establish its permeability through the eye. 
In terms of the first aim, we hypothesized that if curcumin could be encapsulated in a 
liposome, the bioavailability of curcumin would increase. Additionally, the hydrophobic 
curcumin would remain in the lipid bilayer of the liposome allowing it to be delivered to 
target locations. In terms of the second aim, we hypothesized that RPE cells that are 
treated with the curcumin-loaded NLs would reduce oxidative stress. In terms of the third 
aim, we hypothesized that the curcumin-loaded NLs delivered to excised porcine eyes 










Aim I: Synthesis of the Curcumin-loaded Nanoliposomes 
Preparation of Solutions 
Cholesterol. Powdered cholesterol was purchased from Avanti Polar Lipids.  A stock 
solution was created by dissolving 12.5 mg of cholesterol in 1 mL of chloroform.  
Curcumin. To prepare the free curcumin solution, curcumin purchased from Sigma 
Aldrich (97% purity) was dissolved at 25 mg/mL in dimethyl sulfoxide (DMSO) and 
stored at 4°C to maintain stability. This stock solution was then diluted for all liposomal 
preparation, in vitro and ex vivo studies. 
Preparation of the Curcumin-loaded Nanoliposomes. Curcumin-loaded NLs were 
prepared using the thin-film hydration method. Egg yolk phosphatidylcholine (Avanti 
Polar Lipids) and cholesterol solutions were both dissolved in chloroform and then mixed 
in a 4:1 molar ratio respectively. Curcumin was added in a 1:1 molar ratio with the total 
amount of lipids (phosphatidylcholine and cholesterol) into a glass vial.  Though 
curcumin is naturally fluorescent in the visible green spectrum, a molecular probe, 
lissamine rhodamine B (Avanti Polar Lipids), was added at a molar ratio of 1:2000 of 
dye: phosphatidylcholine in order to fluorescently tag the phosphate heads of the 
phosphatidylcholine and allow for better visualization. The lissamine rhodamine B tag 
was fluorescent in the visible red spectrum. 
Once the lipids were thoroughly mixed, the vial was rotated slowly to spread an 
even film along the sides of the container. The excess chloroform solvent was then 
removed by placing the vial in a vacuum chamber for three hours in order to obtain a dry 





Upon rehydration of the film, the phospholipids self-assembled into vesicles featuring 
lipid bilayers; the aqueous solution is pushed toward the hydrophilic heads, while the 
hydrophobic tails host an environment favorable for the curcumin – inside the bilayer 
itself. Twelve hours after rehydration, the NLs were extruded through 200 nm 
polycarbonate membranes (Avanti Polar Lipids) using an extruder (Avanti Mini 
Extruder, Avanti Polar Lipids) to obtain a homogeneous solution of 200 nm diameter 
NLs. 
Characterization of the Curcumin-loaded Nanoliposomes. Microscopy techniques were 
used to visualize the NLs for qualitative analysis. Nanoparticle tracking analysis (NTA) 
and ultraviolet-visible (UV-Vis) spectroscopy were used to determine size and 
encapsulation efficiency of the curcumin-loaded NLs respectively. Langmuir trough 
monolayer studies were also conducted to investigate the liposome membrane 
characteristics and the effect of curcumin on membrane stability. 
Microscopy. The Olympus IX71 (Olympus Corporation) microscope was used to conduct 
standard fluorescent microscopy techniques that were used for the clear, quantifiable 
tracking of both the empty and curcumin-loaded NLs within cells and during ex vivo 
testing. As lissamine rhodamine B has an emission wavelength of 583 nm (Avanti Polar 
Lipids, 2017), all NLs were visualized using the FITC filter. 
Nanoliposome size. Nanoparticle tracking analysis, through the Malvern NanoSight 
LM10 (Malvern Instruments), allows characterization of nanoparticles from 10 nM-2000 
nM in the sucrose solution in which it is rehydrated. NTA uses direct observation and 
measurement of diffusion to analyze the nanoparticles. The NanoSight dually utilizes 





from this method include particle size distribution and statistics, concentration, and visual 
rendering of the curcumin-loaded NLs (Filipe, Hawe, & Jiskoot, 2010). 
The curcumin-loaded NLs were prepared for the NanoSight LM10 by taking the 
rehydrated liposome solution, described prior in the methodology section, and diluting it 
1:10000 in a 0.270 M sucrose solution in preparation for the imaging process. This 
created the clearest imaging for the NanoSight. 
Encapsulation Efficiency. UV-Vis spectroscopy offers a clear, convenient procedure to 
quantify curcumin concentration within the curcumin-loaded NLs. The concentration of 
curcumin-loaded NLs was analyzed using a UV-spectrophotometer (NanoDrop 1000, 
Thermo Scientific) and a standard calibration curve.  
The standard curve was made by initially dissolving free curcumin in DMSO to 
make a 0.6 M curcumin stock solution. A 1:3 serial dilution was used to dilute the 
curcumin stock solution in 0.270 M sucrose solution to make solutions with final 
curcumin concentrations between 1 nM and 2 mM. The concentrations in the samples 
were then quantitatively measured through UV-Vis spectroscopy, using the NanoDrop. 
The blank was sucrose when creating the standard calibration curve but for all subsequent 
experimentation where the concentration of curcumin in the curcumin-loaded NLs was 
being measured, the blank was empty NLs. Though literature showed that the excitation 
wavelength for curcumin is 424 nm (Kunwar et al., 2006), preliminary testing showed 
that the curcumin signals were stronger at 416 nm. Therefore, all subsequent UV-
spectrophotometry experimentation were conducted at an excitation wavelength of 416 
nm. Measurements were taken in triplicate to ensure accuracy in data. The average 





linear relationship between absorbance and concentration of curcumin in a sucrose 
solution.  
Beer- Lambert Law: 𝐴 = 𝑎! ⋅  𝑏 ·  𝑐 
where A= absorbance, 𝑎! =wavelength-dependent absorptivity coefficient (found 
from the slope of the standard curve), b= path length (taken to be 1), and c= 
concentration. 
The experimental NLs were similarly analyzed by taking multiple absorbance 
measurements at 416 nm. The concentrations of curcumin in the curcumin-loaded NLs 
were calculated by applying the linear relationship obtained from the standard curve. 
The encapsulation efficiency of the NLs was quantified using the following 
equation: 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
𝐿𝑜𝑎𝑑𝑒𝑑 𝑐𝑢𝑟𝑐𝑢𝑚𝑖𝑛 𝑐𝑜𝑛𝑐.
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑢𝑟𝑐𝑢𝑚𝑖𝑛 𝑐𝑜𝑛𝑐. ×100, 
 
where loaded curcumin refers to the concentration of curcumin determined from 
UV-spectrophotometry data and Beer-Lambert Law calculations and initial 
curcumin refers to the concentration of curcumin added to the curcumin-loaded 
NL mixture (21.96 mM). 
Drug Retention Studies. The shelf life of the curcumin-loaded liposomes was 
investigated by measuring the drug retention properties. Specifically, the amount of 
encapsulated curcumin was measured over time to determine the ability of the liposome 
retain the curcumin within its bilayer. Briefly, the nanoliposomes were fully synthesized 
on Day 1 and the absorbance readings were taken in triplicate periodically over a time 
interval of 15 days. The absorbance readings were converted into concentrations using  





efficiency. The efficiencies were normalized with respect to Day 1 and subsequently 
plotted. A linear regression was applied to determine the correlation, if any, between time 
and encapsulation efficiency.  
Langmuir Monolayer Studies. Langmuir monolayer experiments were performed on a 
Langmuir mini trough film balance (Kibron Microtrough XS, Kibron Inc., Finland).  
Preparation. The trough was placed on a stable table and was enclosed by an 
environmental chamber. A 4-well multiwell Teflon microtrough plate (8x14 cm, 2.1 cm 
radius) was used for testing. Before each experiment, the trough was washed with 
ultrapure water and ethanol in sequence three times. The sensor probe was sterilized by 
passage through flame for approximately thirty seconds. The well was filled to the brim 
with ultrapure water, which served as the subphase for all subsequent experiments. The 
trough was calibrated with respect to the surface tension of the water subphase, which in 
this case was 72.8 mN/m. The probe was lowered into the subphase until it was 
approximately 2 centimeters below the surface. Before the start of each trial, the system 
was calibrated and zeroed. The accuracy of the system was found to be 0.001 mN/m. 
Mixtures. Control mixtures of phosphatidylcholine (PC) and cholesterol (C) and 
experimental mixtures of phosphatidylcholine, cholesterol, and curcumin (Cur) were 
prepared at 4:1 PC:C, 1:1 PC:C, and pure PC molar ratios. See Appendix D for specific 
volumes. In all experimental conditions, the total lipid (PC and C) to curcumin molar 
ratio was kept constant at 1:1. The mixtures were diluted 1:50 in chloroform. 
Testing. Each trial was begun by lowering the probe in water for 100 seconds to obtain a 
steady baseline measurement. A 10 µL Hamilton microsyringe (Hamilton Company) was 





lipid was expelled gradually in order to avoid membrane collapse and to create an even 
film on the water surface. The resulting surface tension was recorded with Kibron 
FirmWare until the system reached equilibrium. 
Measurement. The recorded measurement was the ending surface tension value where the 
system reached equilibrium. The differences in equilibrium points between the pure lipid 
mix and the curcumin-lipid mix was compared to determine the effects of curcumin 
uptake by the lipid membranes. 
 
Aim II: Testing the Nanoliposomes in Cell Culture 
Experimental Conditions 
Cell Culture Conditions. The curcumin-loaded NLs were assessed using an in vitro 
oxidative stress model. The Adult Retinal Pigment Epithelial 19 cell line (ARPE-19), 
purchased from ATCC, was selected in order to test the curcumin-loaded NLs, as this cell 
line was derived from the RPE cell layer in humans and is phenotypically similar to it. 
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM, from Gibco) 
supplemented with 10% Fetal Bovine Serum (FBS, from ThermoFisher Scientific) and 
1% PenStrep (ThermoFisher Scientific). Media was changed every two days, and cells 
were passaged at 90% confluency using 0.25% Trypsin-EDTA (ThermoFisher 
Scientific). Cell lines were maintained in a 37°C in a 5% CO2 atmosphere.  
Test Conditions. The curcumin-loaded NLs , free curcumin, empty NLs, and H2O2 
experimental solutions were diluted using DMEM basal media, for all experiments.  
Induction of Oxidative Stress. Oxidative stress was induced using H2O2. After washing 





Sigma Aldrich was diluted in DMEM basal media to a final concentration of 600 µM. 
Cells were then incubated for 24 hours with this peroxide solution for all experimental 
procedures.  
Curcumin-loaded NLs. The curcumin-loaded NLs were diluted in basal DMEM media to 
a final concentration of 10 µM curcumin. This was done by calculating the concentration 
of NLs, and assuming an encapsulation efficiency of 2-5%, based on the results from 
Aim 1. From this information, we were able to determine the volume required to give a 
final concentration of 10 µM curcumin in the loaded particles.  
Empty NLs. The amount of empty NLs that was tested was calculated from the results of 
the curcumin-loaded NPs. From this information, we determined the total number of NLs 
that were tested. We then tested these many unloaded liposomes in this experimental 
sample.  
Preparation of Fibronectin-Coated Glass Dishes. Glass dishes were coated with a 
Fibronectin solution (10 µL 100x Fibronectin + 90 µL 1X Phosphate Buffered Saline) 
and incubated at room temperature for 2 hours. Dishes were washed 3 times with 1X 
PBS, after which cells were plated.  
Preventative and Treatment Models. We tested our curcumin-loaded NLs using two 
approaches: a preventative model and a treatment model. The preventative condition was 
utilized in order to test the efficacy of the curcumin-loaded NLs as a preemptive measure 
for AMD, and determine whether oxidative damage could be restricted or minimized. 
The treatment model was utilized in order to determine whether the curcumin-loaded NLs 
could be used to reverse or halt damage to cells that underwent oxidative stress. In both 





for 24 hours. All experiments were conducted in triplicate.  
Preventative Model. In the preventative model, cells were washed with basal media 2 
times before being treated with the following conditions: no treatment, free curcumin, 
empty NLs, curcumin-loaded NLs, H2O2, 4% DMSO, 100% DMSO for 24 hours prior to 
oxidative damage with H2O2. Cell viability and reactive oxidative species assays were 
then run at this point.  
 
Figure 4. Preventative Model procedure flowchart 
 
Treatment Model. For the treatment model, cells were initially damaged for 24 hours with 
H2O2 and incubated at 37°C in a 5% CO2 atmosphere. Cells were then treated with the 
same seven experimental conditions (same as in the preventative model) and incubated 
for 24 hours. The cell viability and reactive oxidative species levels were then assayed.  
 





Time Lapse Studies with Fluorescence. In order to demonstrate the need for a curcumin-
loaded NLs delivery system, time lapses of ARPE-19 cells were performed. 500,000 cells 
were incubated in 2 mL of 10 µM of curcumin-DMSO in basal DMEM. The suspension 
was thoroughly mixed to ensure that there was no aggregation of cells or curcumin and 
incubated in a test tube for 24 hours at 37°C. After overnight incubation, the suspension 
was centrifuged at 125g for 7 minutes. The remaining cell pellet was washed with 500 µL 
of 1X PBS and centrifuged at 125g for 7 minutes in order to remove the excess curcumin. 
Cells were then resuspended in 2 mL basal DMEM and plated on Fibronectin coated 
glass dishes, and allowed to adhere overnight. Cells were imaged using the Olympus 
IX71 microscope in brightfield at 10X. The curcumin was imaged at 424 nm. 
Fluorescence images and brightfield images were then overlaid in ImageJ to create a 
composite.  
MTT Assay. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay was used to evaluate the cytotoxicity and effect of the NLs on ARPE-19 cell 
proliferation. The assay utilized a colorimetric approach to assess metabolic activity of 
the cells as determined by the presence of a purple product. MTT would be uptaken by 
cells and reduced to formazan, which could then be detected colorimetrically. Thus, a 
higher amount of formazan would indicate higher metabolic activity and consequently 
more cells.  
The MTT assay was performed according to the protocol from the MTT Cell 
Proliferation Assay Kit purchased from Cayman Chemical Company. 30,000 cells/well in 
100 µL growth media were seeded onto a 96 well plate. All experimental conditions were 





created, 10 µL of the MTT reagent (provided in kit) was added to each well. Plates were 
gently mixed for one minute and incubated at 37°C for 4 hours. 100 µL of the Crystal 
Dissolving Solution (provided in kit) was added to each well and incubated for 18h at 
37°C. Absorbance was read at 570 nm using a Microplate Reader (MolecularDevices 
SpectraMax). All data were normalized with respect to the untreated condition. For MTT 
reagent reconstitution, see Appendix J.  
Reactive Oxygen Species Assay. The Reactive Oxygen Species (ROS) Assay was 
performed in order to assess the antioxidant activity of cells when treated with the 
curcumin-loaded NLs. In this assay, cells were pretreated with a 7’-
Dichlorodihydrofluorescin diacetate (DCFH-DA), a cell-permeable non-fluorescent dye. 
Upon reaction with a reactive oxygen species, such as a free radical, DCFH-DA oxidizes 
to dichlorodihydrofluorescin (DCF), a fluorescent compound that could be quantitatively 
measured. A higher level of DCF would indicate more oxidative species and a lower 
level of DCF would indicate fewer oxygen species, suggesting that there was antioxidant 
activity. For the complete chemical reaction, see Appendix K.  
ROS levels were determined through the procedures from the ROS Activity kit 
purchased from CellBioLabs. 30,000 cells were seeded in a 96 well plate and grown 
overnight. Cells were then washed once with basal DMEM, after which 100 µL DCFH-
DA (1X, diluted in basal DMEM) was added. The plate was then incubated at 37 °C for 1 
hour in the dark with the appropriate experimental conditions. The dye was then removed 
and plates were washed with 1X PBS, after which experimental conditions were added. 
After the preventative and treatment models were created, the ROS assay was conducted.  





the 2X cell lysis buffer was then added to each well, and mixed thoroughly to ensure cell 
lysis. Wells were then scraped to detach the cells completely. The plate was then 
incubated at room temperature for 5 minutes to allow lysis reaction to occur. 150 µL of 
the solution was transferred to another 96 well plate and read at 480 nm excitation and 
530 nm emission using a microplate reader (MolecularDevices SpectraMax). ROS levels 
were quantified based on standard solutions (provided in kit) and extrapolating from the 
line of best fit. 
 
Aim III: Drug Delivery Testing 
The curcumin-loaded NLs topical solution was tested in an ex vivo eye model in order to 
demonstrate its efficacy and permeability. We proposed that curcumin-loaded NLs 
solution can (1) significantly permeate the layers of the eye and (2) localize in target 
tissues. 
Eye Dissection. Fresh porcine eyes were obtained from Wagner’s Meats (Mount Airy, 
MD, USA) in order to carry out permeability experimentations. Eyes were dissected by 
using dissection scissors to divide the anterior and posterior sections. The anterior portion 
of the eye and vitreous humor were then discarded and the posterior eye, comprised of 
the choroid and retina, was used for experimentation. 
Franz Diffusion Chamber.  Five mL of PBS was introduced into the Franz diffusion cell 
(see Appendix C) and the posterior eye was placed on the apparatus. After enclosing 
these layers in the capsule, 200 µL of the curcumin-loaded NL solution was placed on top 
of the tissue. The Franz cell was run for approximately 180 minutes to allow for complete 





of the porcine eye was removed and washed with PBS in order to remove any fluid, 
including excess curcumin-loaded NL solution, that may have just been resting on the 
exterior of the eye. The ex vivo eye tissue was then imaged for the lissamine rhodamine B 
probes that marked the presence of the curcumin-loaded NLs. After initial examinations 
with the Franz cell running the full 180 minutes cycle, time-lapse studies were conducted 
in order to determine the influence of time on curcumin uptake. In these studies, the 




Size Distribution. A t-test on the size distribution and a F-test on the variations of these 
distributions was calculated, both at α = 0.05. The size distributions were taken from the 
nanoparticle tracking analysis from the NanoSight LM10 model. The NanoSight LM10 
counted the number of nanoparticles it tracked, counting as a number in the size 
distribution. These numbers are factored into the sample size. 
A two-tailed t-test was conducted on the size distributions of three samples each 
of both curcumin-loaded and blank NLs. This t-test was conducted to determine the 
statistical significance between the mean diameter of the two distributions.  
An f-test was also conducted on the size distributions of three samples of 
curcumin-loaded and blank NLs. The F-test was conducted to calculate statistical 
significance between the standard deviation in the mean diameter of the two distributions. 
The test was run with the alternate hypothesis that the blank NLs had a lower standard 





to be statistically significant. 
Langmuir Monolayer Studies. All Langmuir trough experiments were run multiple times 
for each experimental group: 4:1 PC:C (n = 5), 4:1 PC:C/Cur (n = 4), 1:1 PC:C (n = 6), 
1:1 PC:C/Cur (n = 5), pure PC (n = 4), and pure PC/Cur (n = 7). Sample size differed 
between experimental groups due to omission of trials that were found to be outliers (± 1 
standard deviation from the mean). All data are reported as mean ± standard error.  
A two-tailed, unpaired t-test of unequal variance was conducted to determine the 
statistical significance between the average surface pressures of the control (monolayers 
with no curcumin added) and the experimental groups (monolayers mixed with 
curcumin). Statistical significance was determined at the confidence level of p < 0.05. 
MTT Assay. All in vitro studies were conducted in triplicate. Three biological replicates 
were the completed per experiment and averaged for each figure. ANOVA was initially 
used to determine statistically significant differences at α = 0.05.  
A paired t-test was then conducted for all comparisons. Post-hoc analysis was also done 
after ANOVA using the Bonferroni correction at α = 0.003. Cell viability was normalized 
with respect to the control groups that were not treated with any experimental conditions, 
defined as: 
 𝑉 = !!"#
!!"#
 , 
where V denotes cell viability of the experimental condition of interest, Aexp its 
average absorbance, and Acon the average absorbance of the untreated control. 














where σx denotes the experimental error associated with the variable x. From the 














where F is the fold change, R2 the ROS values after the second step of each 
model, and R1 the ROS values after the first step of the model. As with the cell 
















Aim I: Synthesis of the Curcumin-loaded Nanoliposomes 
Microscopy. NLs were imaged under both brightfield and fluorescence in order to 
confirm the success of both the extrusion process and the attachment of the lissamine 
rhodamine B tag. Figure 6 shows that the extrusion process was able to transform the 
liposome solution from heterogeneous mixture of different sized particles (Figure 6a) to a 
homogenous solution of 200 nm nanoliposomes (Figure 6b). Uniform circular 
fluorescence was visible under fluorescence microscopy, confirming the successful 
production of NLs. Fluorescence was viewed under FITC filter to visualize the lissamine 
rhodamine B tag on the NLs (Figure 7). The NLs appeared to be discrete particles, 
signifying that the self-assembly into spherical liposomes was successful.  
  (a)                  (b) 
Figure 6. Images of curcumin-loaded NLs under brightfield microscopy. Liposomes were 







Figure 7. Image of extruded curcumin-loaded NLs using fluorescence microscopy. 
Lissamine rhodamine B tag on the NLs was visualized using FITC filter. NLs were 
diluted 1:100 in glucose for better visualization.  
 
Size Distribution.  Dynamic light spectroscopy was used to verify size distribution of our 
produced NLs. In measuring the size distribution of our NLs, we measured the extruded, 
homogenous liposome solution, which was diluted to 1:10000 to match the concentration 
range of the NanoSight LM10. From the data collected, we observed a size distribution, 
consistent throughout the various types of NLs created. 
Size distributions were created for NLs both unloaded and loaded with curcumin. 
A sample size distribution graph can be seen in Figure 8.  Over three trials, the mean 
diameter for empty NLs was 192 ± 57.7 nm, while the mean diameter for curcumin-






Figure 8. Sample size distribution graph of curcumin-loaded NLs. Sample was diluted at 
1:10000 in sucrose.  
 
Aside from the 4:1 PC:C ratio, size distributions were also measured for a 1:1 
ratio, and at a half curcumin concentration, encapsulated in pure phosphatidylcholine. 
Over two trials, the 1:1 PC:C ratio generated a 222 nm diameter average, with a 98.5 nm 
standard deviation, while the half curcumin concentration in pure phosphatidylcholine, 
over three trials, produced a 200 nm diameter average, with an 89 nm standard deviation. 
Encapsulation Efficiency. To calculate encapsulation efficiency of our NLs, we 
measured the absorbance of curcumin samples at 416 nm over three separate trials. From 
this data, we created a standard curve for curcumin in sucrose at 416 nm. A linear 
regression was applied to the resulting curve and a R2 value of 0.9991 was obtained 





calculations to measure encapsulation efficiency of our NLs. Over three trials, the 
calculated encapsulation efficiency averaged 2.55%, with a standard deviation of 0.158%.   
Drug Retention Studies. In addition to general encapsulation efficiency trials, we also 
ran time-lapse encapsulation efficiency experiment over the course of fifteen days in 
order determine the drug retention properties of the NLs. Absorbance readings were 
taken in triplicate. We saw a strongly correlated (R2 = 0.994) negative linear trend 
between encapsulation efficiency and time. By day 15, our NLs retained 79% of the 
originally loaded curcumin (Figure 9). 
 
Figure 9. Concentration of curcumin retained within curcumin-loaded NLs over a period 
of 15 days, depicted in terms of encapsulation efficiency. All data was normalized to the 
encapsulation efficiency calculated on Day 1. Data is depicted as mean ± standard 
deviation (standard deviation was < 0.02 for all data points). n=1. 
 
Langmuir Monolayer Studies. Figure 10 depicts the surface pressures in the mixture 
phosphatidylcholine and cholesterol monolayers at different PC:C ratios, and the same 





to determine the effect of lipid composition on curcumin uptake. The 4:1 PC:C ratio was 
the only mixture where the surface pressure increased after the addition of curcumin. The 
average surface pressure for the pure 4:1 lipid monolayer was 33.7 ± 1.4 mN/m. 
Meanwhile, the average surface pressure for the mixed 4:1 lipid monolayer with 
curcumin was seen to have increased to 42.0 ± 1.3 mN/m. 
 
Figure 10. Comparison of average surface pressure π between lipid monolayers and 
mixed curcumin-lipid monolayers. Three different molar ratios of PC and C were 
compared. Data is depicted as mean ± standard error. PC: Phosphatidylcholine, 
Cholesterol. *p-value < 0.05 statistically significant when compared to pure lipid 
monolayer of the same mixture ratio. 4:1 PC:C (n = 5), 4:1 PC:C/Cur (n = 4), 1:1 PC:C (n 
= 6), 1:1 PC:C/Cur (n = 5), pure PC (n = 4), and pure PC/Cur (n = 7). 
 
Both 1:1 PC:C and pure PC lipid composition showed a slight decrease in the 
surface pressures between the pure lipid and mixed monolayers. For the 1:1 PC:C pure 
lipid monolayer, the average surface pressure was 25.4 ± 1.7 mN/m which then decreased 
to 22.4 ± 1.8 mN/m with the introduction of curcumin to the monolayer. The pure PC 
lipid monolayer showed a similar trend. The pure lipid film had a surface pressure of 30.6 





pressure of 30.0 ± 1.6 mN/m. 
 An unpaired, two-tailed t-test of unequal variance was used to evaluate the 
statistical significance of the incorporation of curcumin on the surface pressure. The test 
was run between the pure lipid and mixed curcumin-lipid monolayers of each mixture 
group. At α = 0.05, only the 4:1 PC:C mixture was found to be statistically significant 
with a p-value of 0.0047. 
 
Figure 11. Change in average surface pressure per µL of lipid (PC+C) after the 
incorporation of curcumin for all three mixtures. Positive values indicate an increase in 
surface pressure after the addition of curcumin while negative values indicate a decrease 
in surface pressure. Data is depicted as mean ± standard error. Combining pure lipid and 
mixed curcumin-lipid monolayer trials, 4:1 PC:C (n = 9), 1:1 PC:C (n = 11), pure PC (n = 
11) 
  
In Figure 11, the change in the average surface pressures between the pure lipid 
film and mixed curcumin-lipid film was calculated by subtracting the mean surface 
pressure of pure lipid monolayer from that of the mixed curcumin-lipid monolayer. 





different mixtures due to instrument constraints, the calculated surface pressure was 
normalized to the volume of lipid added in order to prevent skewed surface pressure data 
that may result from the weight of the lipid film itself. Positive values indicated an 
overall increase in surface pressure with the addition of curcumin while negative values 
showed a decrease in surface pressure. The greatest difference in surface pressure was 
observed in the 4:1 PC:C lipid composition, with a change of 5.13 ± 0.6 mN/m per µL of 
lipid. The 1:1 PC:C mixture showed a change of -3.68  ± 1.3 mN/m and the smallest 
change in surface pressure was seen in the pure PC at -0.41 ± 0.5 mN/m. 
 
 
Figure 12. Number of curcumin molecules per average change of 1 mN/m for each lipid 
composition. A positive value indicates that the uptake of curcumin molecules causes an 
increase of 1 mN/m while a negative number indicates a surface pressure decrease of 1 
mN/m. Combining pure lipid and mixed curcumin-lipid monolayer trials, 4:1 PC:C (n = 
9), 1:1 PC:C (n = 11), pure PC (n = 11) 
 
Figure 12 depicts the approximate number of curcumin molecules that has to be 
uptaken into by lipid membrane for the surface pressure to change by 1 mN/m. These 





of molecules) of curcumin added to the film mixture by the observed change in surface 
pressure that was shown in Figure 11. The obtained result was the number of curcumin 
molecules responsible for a change in 1 mN/m. A positive value indicated that the uptake 
of curcumin molecules causes an increase of 1 mN/m while a negative number showed 
that the uptake leads to a decrease of 1 mN/m. 
 Results showed that about 8.0 x 1015 molecules of curcumin led to an increase of 
1 mN/m of tension in the 4:1 PC:C lipid mixture. A similar magnitude of curcumin 
molecules, about 1.1x 1016 molecules, was responsible for the change in pressure for the 
1:1 PC:C though it led to a decrease of 1 mN/m rather than an increase. Pure PC required 
the greatest number of curcumin molecules before a change of 1 mN/m in surface 
pressure could be observed. About 1 x 1017 molecules, which is almost 10 times more 
molecules than seen for the other two mixture ratios, were required to decrease the 
surface pressure by 1 mN/m. 
 
Aim II: Testing the Curcumin-loaded Nanoliposomes in Cell Culture 
The MTT assay was used to determine whether our curcumin-loaded NLs 
promoted cell viability in ARPE-19 cells.  We tested the curcumin-loaded NLs’ 
therapeutic potential in two ways: a preventative model and a treatment model. 
Additionally, we measured antioxidant activity using the ROS assay. We tested the 
curcumin-loaded NL’s potential to reduce the production of reactive species in ARPE-19 
cells.  
In the preventative model, cells were pre-treated with the experimental conditions 





shown that 600 µM is sufficient to induce oxidative damage in cells, and this time point 
has been used in several oxidative stress models to evaluate therapeutic efficacy (Kim et 
al., 2003). In the treatment model, cells were initially damaged for 24 hours with 600 µM 
H2O2 and then cells were treated with experimental conditions.  MTT reagents were then 
added and assayed in both models. All data collected for the cell viability studies were 
normalized with regards to the cells that were untreated. 
Optimization of Experimental Condition Parameters 
Curcumin-DMSO Concentration. Optimization studies were first done to determine the 
concentration of curcumin-DMSO that should be tested for encapsulation purposes. To 
overcome the poor solubility of curcumin, we dissolved it in 1 mL of DMSO and verified 
that the concentration of DMSO used in this study would not affect cell viability. From 
our calculations, we determined that our curcumin solutions contained 4% DMSO 
weight/volume. In Figure 13, our optimization studies demonstrated that ARPE-19 cells 
treated with this concentration of DMSO had >95% cell viability (p > 0.05 when 
compared to untreated cells, indicating that there was no difference in viability the two 
conditions). As a result, we were able to ascertain that differences in cell viability were 








Figure 13. DMSO cell viability studies. Due to the poor solubility of curcumin, we 
reconstituted it in DMSO and tested to see whether the presence of DMSO would affect 
cell viability (* p < 0.05 when compared to basal media treated cells). n=3 technical 
replicates and expressed as mean ± standard error)  
 
After this, we then tested various concentrations of curcumin-DMSO. From these 
experiments, we determined that 10 µM of curcumin-DMSO ensured cell viability >60% 
(Figure 14). These results corresponded with literature values, which state that 20 µM of 







Figure 14. MTT Assay for Determining the Concentration of curcumin-DMSO needed 
for synthesizing the liposomal-curcumin complex. ARPE-19 cells were treated with 
varying concentrations of curcumin-DMSO for 24 hours. Plates were then assayed at this 
time point. Viability was normalized to the untreated cells. ANOVA gave p < 0.05 (* p < 
0.05 when compared to untreated cells). n=3 technical replicates and expressed as mean 
± standard error)   
 
Hydrogen Peroxide Concentration. 600 µM of H2O2 was determined to be optimal for 
inducing oxidative stress in ARPE-19 cells, as we retained >70% viability with respect to 
the untreated cells (p < 0.05). These results corresponded with previous literature values 
which demonstrated that 500-700 µM H2O2 was sufficient to induce oxidative stress in 






Figure 15. MTT Assay for Determining the Concentration of H2O2 needed to induce 
oxidative damage. ARPE-19 cells were treated with varying concentrations of H2O2for 24 
hours. Plates were then assayed at this time point. Viability was normalized to the 
untreated cells. ANOVA: p < 0.05. (* - p<0.05 when compared to untreated cells). n=3 
technical replicates and expressed as mean ± standard error  
 
Liposomal Mixture Dilution. We also verified that our curcumin-loaded NLs were not 
cytotoxic. As seen in Figure 16, optimization studies showed that our mixture of lipids 
maintained cell viability at >90% (p > 0.05 when compared to untreated cells). As a 
result, we were able to determine that differences in cell viability were due to the 







Figure 16. Viability of ARPE-19 cells when treated with varying dilutions of empty 
liposomes in cell media. Cell data was normalized with respect to lipid free basal media 
and assayed 24 hours after addition of experimental conditions. ANOVA: p < 0.05. (* 
p<0.05 when compared to untreated cells). n=3 technical replicates and expressed as 
mean ± standard error  
 
Time-lapse of Curcumin-DMSO. Several studies have demonstrated that high doses of 
curcumin result in cell death and apoptosis. As a result, for our studies, we decided to 
choose a dose of curcumin to encapsulate into curcumin-loaded NLs that, when uptaken 
into the cell, would not induce any cytotoxic effects. ARPE-19 cells were treated with 10 
µM of free curcumin and imaged under brightfield for cell morphology. Figure 17 
showed that cell morphology and viability changed considerably. Cells appeared to be 
undergoing blebbing, an indicator of apoptosis at 25 µM and 50 µM. These results were 
also quantitatively measured (Figure 14). Curcumin was seen to promote cell viability at 
low doses but caused cell death at high doses. ANOVA and t-test statistical tests 
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Figure 17. Representative brightfield microscopy images are also shown for a) 0 µM, b) 







Preventative Model. Due to the antioxidant and retinoprotective properties of curcumin, 
we decided to test our curcumin-loaded NLs in a preventative model. Cells were pre-
treated with experimental conditions for 24 hours and then damaged with 600 µM of 
H2O2 for 24 hours.  
MTT Assay. We were able to successfully damage cells with 600 µM H2O2, as cell 
viability reduced by 40%. In addition, viability reduced by 87% in the DMSO treated 
cells. Cell viability increased by 55% in the cells treated with curcumin-loaded NLs  
(p < 0.05) with respect to the untreated cells, indicating that our curcumin-loaded NLs 
may have potentially protected cells and promoted cell viability in general (Figure 18). 
However, since AMD is characterized by a buildup of oxidative stress, we compared the 
effectiveness of our curcumin-loaded NLs to cells that had undergone comparable 
oxidative stress. From these results, we found that cell viability increased by more than 
60% (p < 0.05) with the addition of the curcumin-loaded NLs. These results suggested 
that our curcumin-loaded NLs could be beneficial in reducing some of the cytotoxic 
effects of oxidative stress. Due to curcumin’s poor bioavailability, we decided to compare 
the effectiveness of our curcumin-loaded NLs to that of curcumin-DMSO. We 
demonstrated that cell viability increased by more than 50% (p < 0.05) in treated cells. 
However, the empty NLs also increased cell viability, as we demonstrated that viability 
increased by 26% with respect to the untreated cells. These results would need to be 
confirmed with further mechanistic studies regarding the curcumin-loaded NLs and 







Figure 18: MTT assay of ARPE-19 cells after pre-treatment with liposomal-curcumin 
complex. Cells were pre-treated for 24 hours and then damaged with hydrogen peroxide 
for 24 hours. Plates were assayed after peroxide damage. Data was normalized with 
respect to cells treated with basal media and damaged. (# - p < 0.05 when compared to 
H2O2 treated cells. * - p < 0.05 when compared to curcumin-DMSO.) n=3 replicates and 
expressed as mean ± propagated error 
 
ROS Activity. Due to the increase in viability in the curcumin-NL condition, we decided 
to assay for antioxidant activity using the ROS assay. In this experiment, we assayed 
ROS levels before the addition of H2O2 and after the addition of it, in order to obtain a 
basal metabolic ROS level in these cells. As a positive control, we decided to use 600 µM 
H2O2, as it is a known producer of ROS. We used curcumin-DMSO as a negative control, 
since curcumin is a known reducer of radical species and an antioxidant. We then 
normalized the data with respect to the ROS levels before the addition of H2O2 and 
plotted as a fold change. 





successfully. As seen in Figure 19, there was a 2-fold increase in the ROS levels with 
respect to the controls. We also demonstrated that ROS levels increased by 7-fold in the 
curcumin-DMSO cells. This suggested that although curcumin may be an antioxidant, its 
antioxidant activity could be impacted after the addition of peroxide. However, our 
curcumin-loaded NL treated cells showed that ROS activity increased by 2.5-fold. These 
results suggested that curcumin may be effective as preventative for oxidatively stressed 
cells in an encapsulated form. 
With respect to the cells that underwent oxidative stress, there was only a 0.5-fold 
difference between these cells and our complex-treated cells. These results suggested that 
although we induced oxidative stress, our complex may not be as effective at preventing 
further damage. With regards to the curcumin-DMSO cells, there was a 4-fold change 
difference between these cells and the complex treated cells. These results showed that 
encapsulating curcumin may have allowed for us to reduce ROS levels better than if it 
were unencapsulated. Interestingly, the fold change difference between our control and 
complex was minimal, suggesting that the ROS bioactivity between the two samples was 








Figure 19. Fold change of ROS value when ARPE-19 cells were pre-treated with the 
liposomal complex. Cells were assayed for ROS values pre-damage and post-damage 
with hydrogen peroxide. Fold change was then calculated by dividing the post-damage 
ROS values by the pre-damage ROS values. n=3 technical replicates and expressed as 
mean ± standard error  
 
Treatment model 
MTT assay. We also decided to test our curcumin-loaded NLs’ ability to be used as a 
treatment for cells that had already undergone oxidative stress, as curcumin is known to 
affect this pathway. Cells were damaged with 600 µM H2O2 for 24 hours and then treated 
with experimental conditions as seen in Figure 20. Similar to the preventative model, we 
were able to successfully damage cells with 600 µM H2O2, as cell viability reduced by 
40%. In addition, viability reduced by 85% in the DMSO treated cells. Cell viability 
increased by 28% in the curcumin-loaded NL treated cells (p < 0.05) with respect to the 
untreated cells, indicating that our curcumin-loaded NLs may be beneficial in promoting 
cell viability overall. With respect to the oxidative stress induced cells with no added 
treatments, we found that cell viability increased by 55% (p < 0.05). These results 





effects of oxidative stress.  
However, we found that there was no statistically significant difference in cell 
viability between the cells that were exposed to the curcumin-DMSO and cells that were 
exposed to our curcumin-loaded NLs (p > 0.05, 8% increase in viability). Our results 
demonstrated instead that there was a statistically significant increase in viability between 
curcumin-DMSO and cells that were oxidatively stressed, indicating that curcumin has 
potential to be used as a treatment.   
 
 
Figure 20. MTT assay of ARPE-19 cells after induction of oxidative stress with hydrogen 
peroxide. Cells were damaged with hydrogen peroxide for 24 hours and then treated with 
the liposomal complex solution 24 hours. Plates were assayed after treatments were 
applied. Data was normalized with respect to cells that were damaged and then treated 
with basal media. #p < 0.05 when compared to H2O2 treated cells. *p < 0.05 when 
compared to curcumin-DMSO. 
 
ROS Activity. We assayed ROS levels after cells were treated with H2O2 and after they 
were treated with experimental conditions. As seen in Figure 21, there was a 0.45-fold 





induce radical production. However, compared to the fold changes observe in the 
preventative model, we found that our formulation did not cause as dramatic of a fold 
difference in the treatment model. There was a 0.1-fold difference between the control 
and curcumin-DMSO samples, indicating that the curcumin was able to affect antioxidant 
activity.  
With respect to the peroxide treated cells, the curcumin-loaded NLs fold change 
difference was 0.1 lower. These results suggested that our complex may not have been as 
effective at reducing the ROS levels in cells that have already experienced oxidative 
damage. With respect to the curcumin-DMSO treated cells, our complex had a 0.05 lower 
fold change difference. Interestingly, the largest fold change difference was between the 
control and the complex (0.15). These results suggest that as a treatment, our liposomal 










Figure 21.  Fold change of ROS value when ARPE-19 cells were initially damaged with 
hydrogen peroxide. Cells were assayed for ROS values pre-treatment and post-treatment 
with the liposomal complex. Fold change was then calculated by dividing the post-
treatment ROS values by the pre-damage ROS values. n=1 replicate.  
 
Aim III: Drug Delivery Testing 
For ex vivo testing, we used a fluorescence microscope (Olympus IX71, Olympus 
Corporation) and a Franz diffusion cell to qualitatively observe the diffusion of the NLs 
through the retina and choroid of the eye at several time points. The curcumin-loaded 
NLs were allowed to pass through at 60, 135, and 210 minutes. After analyzing the 
microscopy images through ImageJ (Figure 22), we were able to image the fluorescent 
curcumin-loaded NLs, suggesting that they were able to successfully permeate through 
the layers of the posterior layers of the eye, namely the choroid and sclera.  
         There was not a discernable difference between the three images taken about an 
hour apart. We saw no major trend in the amount of fluorescent particles in the images.  
This suggested that hourly was too long of a time scale and that the NL concentrations 





           For comparison, we also presented the diffusion of empty NLs through the eye 
(Figure 23). For this particular experiment, non-extruded NLs were used with a diffusion 
time of 180 minutes. Immediately, one can see that the faintly fluorescent background is 
not present in this image. 
 
Figure 22. Fluorescence microscopy of the curcumin-loaded NLs diffused through the 















Age-related macular degeneration is a debilitating disease that affects millions of 
adults worldwide. It is primarily caused by the buildup of oxidative stress in the eye, 
causing the death of RPE cells in the retina and eventually leading to irreversible 
blindness. Curcumin, a powerful antioxidant derived from the spice turmeric, can be used 
as a potential therapeutic for the treatment and prevention of AMD. However, its clinical 
applications are currently limited due to poor bioavailability of curcumin, which makes it 
difficult to effectively deliver the drug to the back of the eye. In this current research, we 
aimed to improve the bioavailability of curcumin by loading it into curcumin-loaded NLs 
and show that it can increase cell viability and reduce oxidative stress in ARPE-19 cells. 
Through our research, we were able to examine and analyze curcumin and its 
ability to be encapsulated within NLs, to retain antioxidant and retinoprotective 
properties after encapsulation, and its potential as an AMD treatment vs. prevention 
method. Additionally, we were able to determine the ability of the curcumin-loaded NLs 
to successfully reach the retinal layer of the eye.  
 
Curcumin Encapsulation in Nanoliposomes 
In pertinence to the size distribution experimentation, the results obtained suggest 
that when prepared in the same way, curcumin-loaded NLs are produced with 
approximately the same diameter as the empty NLs. There is a statistically insignificant 
difference between the diameters of curcumin-loaded and empty NLs using t-test 
statistical methods (p > 0.05). However, using an F-test, there is a statistically significant 





alpha level. A statistical comparison between the empty and curcumin-loaded NLs finds 
that the curcumin-loaded NLs have a higher standard deviation than the empty NLs. This 
statistical test shows that there is a greater variation, or less precision, in size distribution 
between our curcumin-loaded NPs and empty NPs 
The NLs created have a wider size distribution than comparable extruded 
subjects: Liposome-Encapsulated Hemoglobin Blood Substitutes (LEHb). A paper by 
Arifin and Palmer (2003) on this subject used extrusion on LEHb, with a 200 nm filter, 
and created a monodisperse NL population, with distribution width of 20 nm. The 
thoroughness in extrusion used in this study may explain the ability to achieve a 
monodisperse size distribution. The study used successive extrusion steps, starting from 
higher diameter filters (10 passes each), and continuing the process with progressively 
smaller filters until the final filter, 200 nm, where 25 passes were performed (Arifin, & 
Palmer, 2003). Comparatively, our methodology uses 10 consecutive passes with the 200 
nm filter only. The thorough extrusion process presented by Arifin and Palmer produces a 
more homogenous solution of nanoparticles.  
From the Langmuir monolayer studies, the trends seen in Figure 10 suggest that, 
out of the three compositions tested, the 4:1 PC:C lipid mixture is the optimal ratio for 
maximum curcumin uptake. As shown in past studies, an increase in surface pressure 
indicates the inclusion of drug molecules, in this case curcumin, into the lipid monolayer. 
The 4:1 PC:C ratio was seen to be the only mixture that demonstrated this increase in 
surface pressure and, as such, is most suited for use when developing a liposome mixture 
for curcumin encapsulation. This is in accordance with previous literature where the 





structure to allow the insertion of curcumin molecules into the monolayer (Karewicz et 
al., 2011). 
 Both 1:1 PC:C and pure PC showed a slight decrease in surface pressure. Though 
not statistically significant in these present experiments, previous studies have shown that 
this observed decrease does have important implications on membrane stability. 
According to literature, this slight decrease suggests that there is possibly some 
desorption of lipid molecules (Gicquaud, Chauvet & Tancrède, 2003). The addition of the 
curcumin may have caused the partial collapse of the film into the subphase. In the case 
of the 1:1 PC:C specifically, the presence of cholesterol may have disrupted the 
phosphatidylcholine packing in a manner similar to what was seen with the 4:1 PC:C 
mixture. This disturbance may have contributed to the lack of surface pressure increase 
that marks curcumin uptake. Previous studies have shown the presence of cholesterol 
stiffens the lipid membranes and reduces drug permeability (Zhao & Feng, 2006; Liang, 
Mao, & Ng, 2004). In fact, increasing the cholesterol content in the monolayer has been 
shown to reduce the loading of poorly soluble drugs (Moghaddam, 2011). Due to the high 
numbers of cholesterol molecules, the film membrane may have been too impermeable to 
curcumin molecules, which may explain why the overall surface pressure did not 
increase. Furthermore, the high concentration of cholesterol in the mixture likely 
exhibited a strong ordering effect on the membrane (Karewicz et al., 2011). Despite its 
limited permeability, the introduction of even the smallest amounts of curcumin may 
have caused too much of a disturbance and loosened the packing structure, thus 
destabilizing the film. This subsequent desorption of molecules may have been reflected 





The lack of curcumin uptake by the pure monolayer is also supported by previous 
studies. The packing structure of the lipids is already very relaxed without the stabilizing 
effect of the cholesterol. The addition of curcumin only further loosens the monolayer 
(Karewicz et al., 2011). This destabilization effect may have led to partial monolayer 
collapse and contributed to the observed decrease in surface pressure. 
Figures 11 and 12 help to validate the destabilizing effects of curcumin. Figure 12 
shows that the pure PC monolayer requires a greater number of curcumin molecules to 
affect surface pressure in comparison to the 1:1 PC:C mixture. This suggests that 
curcumin has a weaker destabilization effect on the pure PC than the other two mixtures. 
The pure PC mixture was also seen in Figure 11 to have the smallest decrease in pressure 
per volume of lipid, suggesting that the minimal decrease in surface pressure was actually 
due to the weaker destabilizing influence of the curcumin rather than the comparatively 
lower weight of lipid film itself, which is another factor that also could have contributed 
to the desorption of lipid molecules. Conversely, the positive values of the 4:1 PC:C 
mixture in Figures 11 and 12 suggest that the curcumin was successfully uptaken into the 
film and that any destabilization was counteracted by the ordering effects of the small 
amount of cholesterol present in the system. 
Results of this present study, supported by conclusions of past research, have 
shown curcumin to have destabilizing effects on the lipid membrane. Based on these 
preliminary monolayer studies, a combination of phosphatidylcholine and cholesterol, 
specifically in a 4:1 ratio, has been shown to be the most effective of the three mixtures 
tested for stable curcumin uptake. Both too high of an amount and the complete absence 





stability and curcumin uptake. Future studies would investigate different ratios of 
phosphatidylcholine and cholesterol ratios, such as 3:1 PC:C or 5:1 PC:C, in hopes of 
determining the ideal membrane composition for optimal curcumin uptake and vesicle 
stability. 
In regards to encapsulation efficiency, low encapsulation efficiency of curcumin 
has been noted in previous studies. In a study by Takahashi et al. of curcumin loaded in 
lecithin nanoparticles, SLP-PC70 LEC showed an encapsulation efficiency for curcumin 
of 68.0 weight % while SLP-WHITE LEC encapsulated less than 10.0 weight %. 
(Takahashi et al., 2009). It is noted that curcumin has a high binding affinity to 
phosphatidylcholine (Began et al., 1999), therefore the 4:1 PC:C ratio was chosen to 
increase encapsulation efficiency. In a study by Chen et al., the encapsulation efficiency 
of different phospholipid curcumin-loaded NLs found encapsulation efficiencies over 
80% for soybean phospholipids (SPC), egg yolk phospholipids (EYPC), and 
hydrogenated soybean phospholipids (HSPC) (Chen et al. 2012).  
Though the encapsulation efficiency is markedly lower (2.55%) in this present 
research when compared to the aforementioned studies, the amount of curcumin 
encapsulated is nonetheless sufficient for the purposes of retinal drug delivery. RPE cells 
have a known upper dose threshold of 20 µM of curcumin (Hollborn et al., 2013) before 
cytotoxic effects set in. Taking this and the amount of curcumin added to the liposomal 
formulation into account, too high of an encapsulation efficiency would be unfavorable in 
terms of the delivered dosage. Furthermore, results from the in vitro studies show that the 
current amount of curcumin encapsulation still has a positive impact in increasing cell 





efficiency, our curcumin-loaded NLs still show significant potential for use as a 
therapeutic for AMD. Additionally, our time-lapse encapsulation efficiency showed that 
the encapsulation of our curcumin-loaded NLs remained stable over a fifteen-day storage. 
This quality would be important to maintain for a pharmaceutical application. 
 
Prevention vs. Treatment 
In regards to the MTT assay, ARPE-19 cells treated with free curcumin 
(curcumin-DMSO), empty NLs, or the curcumin-loaded NLs all had a higher percent of 
viability and survival in comparison to the control cells that were just damaged with 
H2O2. Regardless of whether the cells were tested in the preventative model, in which 
damage with oxidative stress occurred after treating with the experimental conditions, or 
in the treatment model, in which oxidative damage was induced prior to treatment with 
the conditions, the results still yielded higher percent viability for those specific 
conditions mentioned above. This aligned with our hypothesis regarding the possibility of 
the curcumin-loaded NLs as a therapeutic for oxidative stress. Additionally, it showed 
that these curcumin-loaded NLs had no deleterious effects on the cells. However, there 
were slight differences in regards to percent viability between the two models. 
In the treatment model, we were able to demonstrate similar results with this 
approach, as encapsulated curcumin appeared to increase cell viability with respect to 
free curcumin. This result is interesting, as not much data is available regarding 
curcumin’s potential as a treatment for diseases, which involve oxidative stress. 
However, further studies need to be done to verify this result. Current literature suggests 





much is known about the mechanism that this occurs by. Mirza et al. demonstrated that 
curcumin slowed the rate of ROS progression, and heme oxygenase 1 (HO-1) has also 
been implicated in the curcumin-induced reversal of oxidative stress (McNally, Harrison, 
Ross, Garden, & Wigmore, 2007). Assaying for biomarkers or changes in this pathway 
would also help us determine whether the increase in viability is due to changes in 
oxidative stress levels. Another approach to consider would be performing a similar panel 
of oxidative stress biomarkers, as oxidative stress is defined as changes in a variety of 
biomarkers. Potential biomarkers include protein carbonyl and DNA damage; an increase 
in oxidative stress is linked to high levels of protein carbonyl groups and to high levels of 
DNA damage (Dalle-Donne, Rossi, Giustarini, Milzani, & Colombo, 2003). Out of these 
two biomarkers, curcumin has been shown to influence DNA damage the most (Ayyagari 
et al.). Assaying for reversal or attenuation of DNA damage with this model would allow 
us to more conclusively determine how effective this curcumin-loaded NLs is at affecting 
oxidative stress levels. 
In the preventative model, our results demonstrated that cell viability increased in 
the cells that were pre-treated with free curcumin as well as with the curcumin-loaded 
NLs. These results suggest that there may be some retinoprotective properties that allow 
for ARPE-19 cells to be protected from the oxidative damage that was induced by pulse 
delivery of H2O2. These results also correspond to similar studies done on other turmeric 
and curcumin derivatives, which have also been shown to increase cell viability in 
ARPE-19 cells. (Jitsanong, Khanobdee, Piyachaturawat, & Wongprasert, 2011; Hollborn 
et al., 2013). In these studies, both curcumin and their derivatives were also assayed for 





a single biomarker, and as a result, a panel of biomarkers would allow us to assess 
whether our complex would be able to increase cell viability through an antioxidant 
mechanism, similarly to the multiple biomarkers associated with oxidative stress. 
Potential biomarkers include superoxide dismutase and glutathione peroxidase, as 
demonstrated by Jitsanong et al. (2011) for assaying the antioxidant activity of 
curcuminoids. 
In the preventative model, there was a more prominent difference in cell viability 
between the empty liposome and the curcumin-loaded NLs on the ARPE-19 cells than 
that of the treatment model. This suggests that the curcumin-loaded NLs could be more 
beneficial as a preventative method rather than a treatment for AMD. Unexpectedly, it 
was also observed that cells treated with just empty nanoliposomes also increased percent 
viability in a similar manner as the curcumin-loaded NLs in both the preventative and 
treatment models. Specifically in the treatment model, there was no significant difference 
in percent viability between the empty NLs and curcumin-loaded NLs, which may either 
suggest a possibility of therapeutic properties from the mixture of lipids and agents 
utilized to construct these NLs or reflect poor encapsulation efficiency of these NLs. 
Phosphatidylcholine, the primary component of the NLs, have been shown to possess 
some antioxidant properties in previous studies. Ghyczy et al. (2008) found that 
phosphatidylcholine metabolites help to inhibit the production of ROS in a small bowel 
organ model, suggesting that phosphatidylcholine does have significant antioxidant 
properties. Phosphatidylcholine also exhibited antioxidant properties in vivo in rat 
models. Demirbilek et al. (2004) found that polyenylphosphatidylcholine, a derivative of 





stress) in rat tissue while Lee et al. (2013) saw that phosphatidylcholine ameliorated renal 
toxicity in rats by enhancing antioxidant enzyme activity such as that of superoxide 
dismutase. Previous studies have also shown the potential of cholesterol, the other main 
component of the NLs,  to act as an antioxidant in rats. For instance, one study found that 
increased cholesterol in rat liver cells increased the activity of catalase, which prevents 
the formation of lipid peroxidation (Mahfouz and Kummerow, 2000). A similar study 
found that cholesterol in rat liver cells increase the activity of the enzyme GSH-Px, which 
also prevents the formation of lipid peroxidation (Yuan, Kitts, and Godin, 1998). An 
additional study found that diets high in cholesterol reduced lipid peroxidation in the liver 
and red blood cells of rats (Yuan and Kitts, 2003). These studies show that cholesterol 
may have moderate antioxidative properties, which could explain why there was no 
significant difference in percent viability between the empty NLs and curcumin-loaded 
NLs. 
 
Retention of Antioxidant Properties 
In order to demonstrate that our curcumin-loaded NLs are effective at increasing 
antioxidant activity, we measured the reactive oxidative species levels in vitro. This 
approach is frequently used as a preliminary screening to determine whether there is 
antioxidant activity in general present in cells that are treated with various compounds. A 
lower level of reactive species indicates that there may be some other antioxidant activity 
that the cell is undergoing due to a therapeutic. 
From our results, we demonstrated that there was a reduction in the relative levels 





curcumin-loaded NLs. In conjunction with our cell viability studies, these results showed 
that our curcumin-loaded NLs increased cell viability through an antioxidant pathway. As 
this concentration of curcumin is known to cause damage, and we observed that there 
was both an increase in viability and a reduction in ROS, there may be reason to believe 
that encapsulating the drug attenuates the overall cytotoxic effect. While the ROS assay 
measured the general trends of ROS levels, more specific mechanisms could be targeted 
as well. These specific substrate tests would need to be done in conjunction as study 
results feature discrepancies regarding the effect of superoxide dismutase, a certain 
enzyme, on antioxidant activity (Sharma et al., 2013; Jia et al., 2011; Yildirim, Ucgun, & 
Yildirim, 2011). However, further studies could verify and better understand this process. 
For instance, time lapses could be performed to determine whether ARPE-19 cells would 
die after prolonged exposure. These findings agreed with similar studies that were done 
to encapsulate curcumin as well. For example, Jithan et al. demonstrated that the release 
of curcumin can be controlled through the use of albumin-nanoparticles. Cyclodextrin has 
also been used to encapsulate curcumin in the food industry, however, there is limited 
research about curcumin encapsulation for the treatment or prevention of retinal 
degenerative diseases (Mangolim et al., 2014). These results show the potential to 
prevent damage in these types of diseases. 
We also tested whether antioxidant activity would be altered by curcumin in a   
treatment model. These results, when compared to the preventative model, showed that 
the antioxidant effect of curcumin was not as prominent when the cells were already 
damaged. This may suggests that curcumin-loaded NLs may be not be impacting 





pathways, when used post-oxidative stress; this corroborates several other studies that 
emphasize curcumin’s ability to protect and prevent damage from oxidative stress, rather 
than treat it. Our results show that there is potential for these curcumin-loaded NLs to be 
used as a treatment but their effects may be less pronounced. Further studies measuring 
ROS levels throughout the course of the experiment could help clarify this distinction. 
 
Mechanism of Nanoliposome Uptake and Curcumin Intracellular Trafficking 
 By elucidating the exact mechanism of liposome uptake by the RPE cells, the data 
from our in vitro studies can be better understood in the context of liposomal drug 
delivery and AMD treatment. The cellular uptake of liposomes is thought to occur in two 
ways: endocytosis and membrane fusion (Düzgüneş & Nir, 1999). As ARPE-19 cells are 
known to uptake liposomes via endocytosis (Peyman, Schulman, & Neisman, 1995; 
Neisman, Peyman, & Miceli, 1997), only endocytosis will be further discussed. 
Endocytosis occurs as the cell membrane engulfs a specific macromolecule in an 
intracellular membrane-bound vesicle, known as the endosome, which is then trafficked 
through the cells, possibly through use of microtubules (Glover, Glouchkova, Lipps, & 
Jans, 2007), to lysosomal compartments (Straubinger, Hong, Friend, & Papahadjopoulos, 
1983) and ultimately to a final destination. In the case of curcumin-loaded NLs, the target 
is the mitochondria, the location where the curcumin is known to modulate lipid 
peroxidation (Zingg et al., 2012). Previous studies have detailed the liposome uptake in a 
variety of cells, thus highlighting the numerous biochemical and physical factors that 
facilitate or inhibit endocytosis. Kang, Jang, and Ko (2017) investigated the endocytotic 





liposomes is dependent on surface charge, as cationic liposomes were internalized more 
quickly when compared to anionic and neutral liposomes. Similar results were obtained 
in studies by Dan (2002), Li et al. (2011), and Soenen, Brisson, & De Cuyper (2009). It 
was theorized that the electrostatic interactions between the cationic surface of the 
liposomes and the negatively charged cell membrane brought the two membranes closer 
together, allowing for increased endocytotic uptake (Elouahabi & Ruysschaert, 2005). 
These same electrostatic interactions had an opposite effect on the anionic liposomes, 
where the same-charge repulsion hindered liposome proximity and subsequently cellular 
uptake (Honary & Zahir, 2013). Nevertheless, several studies (Hong & Papahadjopoulos, 
1992; Bajoria, Sooranna & Contractor, 1997) have found that negatively charged 
liposomes were able to be endocytosed regardless of the electrical repulsion. This 
suggests that the presence of cell receptors and the subsequent ligand-receptor bonding 
can overcome the repulsive electrostatic interactions. Regardless, most, if not all, studies 
agreed that charged liposomes had greater cellular uptake via endocytosis than neutral 
liposomes. This has significant implications for the cellular uptake of our curcumin-
loaded NLs. Made of phosphatidylcholine and cholesterol, these liposomes are mostly 
neutral. As suggested by the previous studies, the lack of a surface charge greatly limits 
the uptake of the NLs by the ARPE-19 cells. This is potentially reflected in the less 
pronounced impact of the curcumin-loaded nanoliposomes on lowering ROS activity 
compared to the free curcumin. It is likely that with the addition of surface charge like 
poly-l-lysine or with the replacement of phosphatidylcholine with a charged lipid such as 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), the NL uptake would greatly 





and the free curcumin. Additionally, lipid composition outside of electrical charge has 
been seen to enhance the endocytosis of the liposomes. In a study by Lee et al. (2013), 
liposome uptake by Schwann cells, endothelial cells, and neural cells via endocytosis all 
increased by 5-,11-, and 8-fold after the addition of cholesterol to the liposome 
composition. To our knowledge there are no similar data with regards to specifically 
ARPE-19 cells but the Lee et al. (2013) study suggests that there could possibly be a 
similar effect on the endocytosis of our curcumin-loaded NLs by the ARPE-19 cells. 
There is a possibility that the addition of more cholesterol to liposome composition could 
increase cellular uptake, resulting in a greater and more prominent reduction of ROS 
activity when compared to the free curcumin. 
Metabolic Trafficking of Curcumin. Curcumin affects several metabolic pathways in the 
cell. It primarily affects cholesterol accumulation and the glutamate transporter. Studies 
have shown that curcumin treated cells tend to have reduced cholesterol accumulation . 
This was seen in Zhao et. al (2012), as they were able to demonstrate that higher levels of 
curcumin resulted in the overexpression of cholesterol efflux biomarkers such as PPARγ, 
LXRα, and ABCA1.  However, these studies interestingly note that curcumin has a 
limited effect on other lipid metabolism genes such as ACAT-1 and 15-LOX (Zhang et. 
al, 2014).  Future studies involving curcumin and retinal oxidative stress should probe for 
the cholesterol accumulation biomarkers, as there is limited research available on how it 
affects ARPE-19 lipid metabolism. 
In addition to the cholesterol metabolism pathways, curcumin also affects the 
glutamate transporter – GLT1 (Zhang et al., 2014). GLT-1 is known to be involved in 





activity and reduced neurotoxicity in cells. There is also limited research available on 
GLT-1 expression in ARPE-19 cells. By assaying for this transporter, and determining 
the relative transporter activity when cells are treated with the curcumin-loaded NLs, we 
may be able to better understand the pathway that this complex takes in vitro. 
Another aspect to consider in curcumin trafficking is RPE65. RPE65 is a protein that is 
involved in the pathogenesis of AMD. Studies have shown that overexpression of RPE65 
causes AMD (Redmond et. al, 1998) . As a result, inhibiting its activity may potentially 
result in a slower rate of progression. By probing for RPE65 activity in curcumin treated 
ARPE-19 cells, we may be able to determine whether curcumin’s retinoprotective 
properties affects AMD development.  
 
Nanoliposome Permeability and Release 
Our drug delivery model demonstrated that curcumin-loaded liposome 
nanoparticles can effectively permeate the scleral and choroidal layers of porcine eyes to 
ultimately reach the retina. Through experimentation with the Franz diffusion cell, we 
were able to simulate a pressurized system similar to that of in vivo eyes. Our results 
indicate, qualitatively, that encapsulating curcumin in NLs allows for the permeability of 
curcumin. However, the qualitative nature of our study does not allow for precise 
conclusions about the diffusion process. In particular, though we observed an increase in 
fluorescent intensity from our time-lapse images, we offer no estimate on the diffusion 
coefficient. 
On a cellular level, it is more difficult to evaluate NL permeation and release, as 





known to bind tightly to encountered cell filaments, so we may only track the NL as far 
as the cell membrane where the lissamine tag and NL contents theoretically separate 
(Sanger, Mittal, & Sanger, 1984). Once the NL permeates into the cell lipid bilayer, it 
partitions based off the difference in solubility between the bilayer and the cytoplasm 
(Kubinyi, 1979). 
We also note a difference between empty and curcumin-loaded NL in 
fluorescence images. In particular, the empty NLs have much more well-defined shapes, 
as opposed to the curcumin-loaded NL images. We are confident that this is not an 
artifact of the imaging process; rather, it appears that the NLs aggregate when formed 
with curcumin, a phenomenon that we also observed in our cell culture microscopy 
studies. Surfactants can be used to increase a molecule's effective solubility. However, 
any use of surfactants should not create a disadvantageous loss in permeability, as the 
effectiveness of a drug is dependent on both (Dahan & Miller, 2012). 
Although the results do not allow us to fully characterize the curcumin-loaded 
NLs’ ability to be implemented via a topical application, such as an eye drop, we are able 
to conclude that it has the ability to permeate the tissues and protein junctions between 
the sclera and choroid. In order to draw more accurate and viable conclusions about the 
NLs permeability and diffusion characteristics, future experimentation would require a 
shortened time scale wherein data are collected in shorter periods than the hourly scale 
used in this study. 
 
Limitations 





a preventative measure, though there are still several considerations with our results. We 
decided to model the oxidative stress that induces AMD is through a pulse delivery of 
H2O2. This approach has been shown in several studies to be a reliable way to model 
AMD, however, AMD is characterized by constant oxidative stress, not an isolated event. 
In order to demonstrate the effectiveness of the curcumin-loaded NLs in a more realistic 
AMD model, we would need to use a system that could constantly generate H2O2. For 
example, glucose oxidase and glucose have been used in conjunction to constantly 
produce peroxide. In a study conducted by Graf and Penniston (1980), the researchers 
demonstrated a colorimetric method to quantify glucose by measuring hydrogen peroxide 
produced from the glucose through glucose oxidase catalysis. Determinations of glucose 
concentrations with glucose oxidase produced hydrogen peroxide in a yield of 73.9% of 
theoretical, and this oxidation yield is substantial enough for consistent reproducibility. 
By doing so, we would be able to more conclusively say that our curcumin-loaded NLs 
could be used to attenuate the effects of AMD. Another limitation is the experimental 
design as an in vitro study. Although it is the logical approach to testing a new 
compound, it limits our ability to make predictions about the in vivo effect of our 
curcumin-loaded NLs. There are other cell types and layers that the treatment would need 
pass through or interact with, which may impact what concentration reaches the retina. A 
quantitative in vivo study would be able to demonstrate the therapeutic’s feasibility to 
penetrate the various layers of the eye and exert a therapeutic effect. 
Another major consideration is drusen levels. Clinically, dry AMD’s pathology is 
defined as and characterized by the buildup of drusen in the retinal layer. In this study, 





biomarkers. By assaying for proteins and lipids that are present in drusen, we would be 
able to conclusively determine whether our curcumin-loaded NLs have a clinically 
significant effect on the progression and development of AMD; these studies could be 
performed in vitro before progressing to an animal model of AMD.  
One of the major limitations of the ex vivo testing was the suboptimal choices of 
fluorescence. As previously mentioned, the excitation wavelength for curcumin is 424 
nm (Kunwar, Barik, Priyadarsini, & Pandey, 2007) while that of the rhodamine tag used 
is marketed at 560 nm. However, we found that the intensity of curcumin’s fluorescence 
is far too low to be imaged by our equipment, which was equipped with the FITC-TRITC 
filter combination (485 nm and 550 nm, respectively). The excitation spectrum of 
curcumin is too narrow to fluorescence significantly under the 485 nm FITC light; rather, 
we observed that the rhodamine tag still fluoresces under the blue light, although much 
more faintly. 
         Ex vivo testing with the Franz cell was originally intended to collect quantitative 
data by determining the concentration coefficient between the original solution and the 
receptor solution. However, the UV-vis spectrometer available through the school was 
not sensitive enough to detect the small concentrations of either curcumin or NLs (via the 
rhodamine tag). This was mainly due to the large volume of the receptor chamber (5 mL) 
of the Franz cell compared to the concentrations obtained by the curcumin-loaded NL 
synthesis process.  







 Our experimentations revealed that curcumin can successfully be encapsulated 
within NLs and increase cell viability in both preventative and treatment applications. 
Additionally, we conclude that the curcumin-loaded NLs have the potential to permeate 
through the posterior portion of the eye in order to reach the retina and exert an 
antioxidative effect.. While our results are promising in answering our research question, 
they are preliminary findings and therefore provide the foundation for future studies in 
pharmaceutical research. Such studies could remediate our limitations in order to make 
more statistically significant conclusions. 
Future investigations would focus on clinical translations of our approach and 
involve in vivo studies to prove that a topical solution can reach the posterior layers of the 
eye as well as deliver a therapeutic amount of curcumin. In conjunction with in vivo 
testing in animal models with AMD, additional surface modifications to the NLs could be 
added to the protocol to better aid both specificity and affinity of to retinal cells. Future 
studies would also require the development of a carrier solution for optimal drug delivery 
and tolerance. Ultimately, our study may lay the foundations for development of a non-
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Appendix A: Glossary  
Absorption Spectrophotometer - instrument used to measure the ability of certain 
molecules to absorb particular wavelengths 
Amphiphilic - used to describe a compound that has both lipid-based and water-based 
properties 
Angiogenesis - process where new blood vessels are created from pre-existing vessels 
Antioxidants - a molecule that inhibits oxidation of other molecules; reduces oxidative 
stress 
Bioavailability - how fast or how much of a substance is absorbed by a living system 
Choroid - connective tissue layer between retina and sclera in the eye 
Drusen - yellow deposits under the retina 
Lysate - preparation of a product of cells, such as protein, DNA, or RNA 
Oxidative stress - a result of the imbalance between reactive oxygen species and the 
body’s ability to detoxify it 
Nanoliposome (NL) - synthesized submicron vesicle composed of a lipid bilayer used in 
drug delivery 
Phosphatidylcholine (PC) - type of phospholipid that is a major component in liposome 
membranes 
Retinal pigment epithelium (RPE) - layer of cells that are located between the 
choriocapillaris and outer segments of the photoreceptors; interacts with these 
photoreceptors to maintain vision 
Retinoprotective - the ability to protect the retina from degeneration; can occur, for 





Vascular endothelial growth factor (VEGF) - a signal protein; responsible for 
stimulating angiogenesis and vasculogenesis 








Appendix B: Curcumin Structure 
Curcumin, 1,3-diketo form. Source: AVA Plant Co., Ltd. (2011). Aquacumin – Water 




















Photograph of the 5 mm clear unjacketed Franz diffusion cell with 12 mm outer diameter 







Appendix D: Standard Curve of Curcumin in Sucrose 
 
A standard curve of curcumin in sucrose was created by plotting absorbance vs curcumin 







Appendix E: Langmuir Trough Monolayer Experiments 
Volumes of phosphatidylcholine (PC), cholesterol (C), and curcumin (Cur) used to 
prepare each mixture. In all mixtures, the total lipid (PC+C) to curcumin ratio was kept at 
a 1:1 molar ratio.  
 
Mixture Total (µL) PC (µL) C (µL) Cur (µL) 
4:1 PC/C 3.38 2.71 0.677 -- 
4:1 PC/C/Cur 5 2.71 0.677 1.61 
1:1 PC/C 1.7 0.85 0.85 -- 
1:1 PC/C/Cur 2.51 0.85 0.85 0.81 
PC 3 3 -- -- 










Appendix F: Nanoliposome Preparation 
 
1. Pipette 76 µL of 32.46 mM phosphatidylcholine solution, 19 µL of 32.46 mM 
cholesterol solution, 45.4 µL of 25 mg/mL curcumin stock, and 2.12 µL of 
lissamine rhodamine B solution into a Fisherbrand™ Class B Clear Glass 
Threaded Vial to achieve a 1:1 ratio of total lipid: curcumin, with a 4:1 ratio of 
phosphatidylcholine: cholesterol. To prepare empty NL, add the same volumes of 
just the phosphatidylcholine, cholesterol, and lissamine rhodamine B solutions. 
2. Layer NL solution against the walls of the vial by slowly rotating the vial 
horizontally for 60 seconds. 
3. Remove the excess solvent through evaporation by placing the glass vial in a 
vacuum chamber for at least 3 hours. 
4. Rehydrate the dry lipid film with 1 mL sucrose. 
5. Store the vials at 4 °C overnight to allow for the self-assembly of the NL 
complex.  
6. Assemble mini-extruder according to the manufacturer’s use instructions, using 
200 µM filters. 









Appendix G: Nanoliposome Viewing Chamber Preparation and Imaging Protocol 
 
1. Form a viewing chamber by coating two opposite sides of a square glass coverslip 
with vacuum grease and placing it gently on a microscope slide, leaving a small 
gap between the uncoated sides of the coverslip and the slide.  
2. Pipette 90 µL of glucose solution through the gap and into the middle of the 
coverslip-slide area.  
3. Extract 10 µL from the top of the NL solution (where there is a greater 
concentration of particles) and pipette it the opening and into middle of the 
glucose solution. 
4. Allow the NL solution to spread throughout the viewing chamber to allow for 
uniform imaging. 









Appendix H: Nanodrop (UV-Vis Spectroscopy) Protocol 
 
Adapted from NanoDrop 1000 Spectrophotometer V3.7 User’s Manual (Thermo Fisher 
Scientific) 
 
1. Clean both the upper and lower pedestals of the sample retention system with 2 µl 
deionized water aliquots and a laboratory wipe. (If decontamination is necessary, 
use 2 µL aliquots of 0.5% sodium hypochlorite solution). 
2. Set the absorbance wavelength for 416 nm for curcumin detection. 
3. Pipette 2 µL of blank solution onto the lower pedestal, lower the lever, and press 
'Blank'. 
4. After measurement has been taken, lift the lever and clean the pedestal of the 
blank solution using a laboratory wipe. 
5. Pipette 2 µL of experimental solution onto the lower pedestal. Lower lever and 
press 'Measure'. 
6. After measurement has been taken, lift the lever and clean the pedestal of the 
experimental solution using a laboratory wipe. 
7. After all measurements have been taken and data recorded, pipette 2 µL of 
deionized water onto both the upper and lower pedestals and clean with a 































Appendix I: Nanosight Nanoliposome Size Distribution Protocol 
 
1. Pipette 400-500 µL of sample or sample dilution into using a 1 mL disposable 
syringe into the platform.  
2. Turn on the machinery and the Nanosight software. 
3. Press ‘Capture’ within the software and focus the image to find a vertical red line 
on the screen.  
4. Image to the left of the red line so that one peak appears on the output and there is 
less red within the viewing screen. (If image is unsatisfactory: filter or dilute the 
sample.) 













Appendix J: MTT Assay Reagent Reconstitution  
 
Protocol adapted from Caymen Chemical’s MTT Cell Proliferation Assay Kit  
 
I. Assay buffer preparation - Prepared by dissolving the Cell-Based Buffer Tablet in 
100 mL of distilled water 
II. MTT Reagent - Prepared by dissolving the MTT Reagent in 5 mL of Assay 
Buffer 
III. Crystal Dissolving Solution - Prepared by dissolving the Crystal Dissolving SDS 
powder with Crystal Dissolving hydrochloride 
 
Chemical Reaction for MTT Assay 
 
This assay operates on the principle of reducing MTT to formazan. MTT is uptaken into 
the cell and reduced by oxioreductases in the cell. Therefore, a high formazan level 






















Appendix K: ROS Assay Reagent Reconstitution  
 
Protocol adapted from Cell BioLab’s Reactive Oxygen Species Assay kit.  
 
I. Dye Preparation - The DCFH-DA dye was prepared by diluting the 20X stock to 
1X in DMEM basal media  
 
Chemical Reaction for ROS Assay 
 
The ROS assay involves the measurement of the DCF dye. Cells initially uptake a 
nonfluorescent molecule, DCFH-DA, which then permeates the cell membrane. When 
this molecule reacts with radical species, it reduces to the fluorescent molecule DCF.  
From: http://www.cellbiolabs.com/sites/default/files/STA-342%20Fig%201.jpg 
